<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cyclical progestogens for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library</title> <meta content="Cyclical progestogens for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001016.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cyclical progestogens for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001016.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001016.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Cyclical progestogens for heavy menstrual bleeding" name="citation_title"/> <meta content="Magdalena Bofill Rodriguez" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="m.bofill@auckland.ac.nz" name="citation_author_email"/> <meta content="Anne Lethaby" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cindy Low" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Iain T Cameron" name="citation_author"/> <meta content="University of Southampton" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD001016.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/08/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001016.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001016.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001016.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Danazol [therapeutic use]; *Intrauterine Devices, Medicated; Medroxyprogesterone Acetate [therapeutic use]; Menorrhagia [*drug therapy]; Progesterone [administration &amp; dosage, *therapeutic use]; Progestins [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Tranexamic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001016.pub3&amp;doi=10.1002/14651858.CD001016.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="6nHUP32m";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001016\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001016\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","th","ms","ja","fa","fr","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001016.pub3",title:"Cyclical progestogens for heavy menstrual bleeding",firstPublishedDate:"Aug 14, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001016.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001016.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001016.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001016.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001016.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001016.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001016.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001016.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001016.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001016.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6400 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001016.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0215"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-sec-0205"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/appendices#CD001016-sec-0220"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/table_n/CD001016StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/table_n/CD001016StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cyclical progestogens for heavy menstrual bleeding</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#CD001016-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Magdalena Bofill Rodriguez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#CD001016-cr-0003">Anne Lethaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#CD001016-cr-0004">Cindy Low</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information#CD001016-cr-0005">Iain T Cameron</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information/en#CD001016-sec-0230">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 August 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001016.pub3">https://doi.org/10.1002/14651858.CD001016.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001016-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001016-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001016-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001016-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001016-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001016-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001016-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001016-abs-0001" lang="en"> <section id="CD001016-sec-0001"> <h3 class="title" id="CD001016-sec-0001">Background</h3> <p>Heavy menstrual bleeding (HMB) is a menstrual blood loss perceived by women as excessive that affects the health of women of reproductive age, interfering with their physical, emotional, social and material quality of life. Whilst abnormal menstrual bleeding may be associated with underlying pathology, in the present context, HMB is defined as excessive menstrual bleeding in the absence of other systemic or gynaecological disease. The first‐line therapy is usually medical, avoiding possibly unnecessary surgery. Of the wide variety of medications used to reduce HMB, oral progestogens were originally the most commonly prescribed agents. This review assesses the effectiveness of two different types and regimens of oral progestogens in reducing ovulatory HMB. </p> <p>This is the update of a Cochrane review last updated in 2007, and originally named "Effectiveness of cyclical progestagen therapy in reducing heavy menstrual bleeding" (1998). </p> </section> <section id="CD001016-sec-0002"> <h3 class="title" id="CD001016-sec-0002">Objectives</h3> <p>To determine the effectiveness, safety and tolerability of oral progestogen therapy taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), in achieving a reduction in menstrual blood loss in women of reproductive age with HMB. </p> </section> <section id="CD001016-sec-0003"> <h3 class="title" id="CD001016-sec-0003">Search methods</h3> <p>In January 2019 we searched Cochrane Gynaecology and Fertility's specialized register, CENTRAL, MEDLINE, Embase, CINAHL and PsycInfo. We also searched trials registers, other sources of unpublished or grey literature and reference lists of retrieved trials. We also checked citation lists of review articles to identify trials. </p> </section> <section id="CD001016-sec-0004"> <h3 class="title" id="CD001016-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) comparing different treatments for HMB that included cyclical oral progestogens were eligible. </p> </section> <section id="CD001016-sec-0005"> <h3 class="title" id="CD001016-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, assessed trials for risk of bias and extracted data. We contacted trial authors for clarification of methods or additional data when necessary. We only assessed adverse events if they were separately measured in the included trials. We compared cyclical oral progestogen in different regimens and placebo or other treatments. Our primary outcomes were menstrual blood loss and satisfaction with treatment; the secondary outcomes were number of days of bleeding, quality of life, compliance and acceptability of treatment, adverse events and costs. </p> </section> <section id="CD001016-sec-0006"> <h3 class="title" id="CD001016-sec-0006">Main results</h3> <p>This review identified 15 randomized controlled trials (RCTs) with 1071 women in total. Most of the women knew which treatment they were receiving, which may have influenced their judgements about menstrual blood loss and satisfaction. Other aspects of trial quality varied among trials. </p> <p>We did not identify any RCTs comparing progestogen treatment with placebo<i>.</i> We assessed comparisons between oral progestogens and other medical therapies separately according to different regimens. </p> <p>Short‐cycle progestogen therapy during the luteal phase (medroxyprogesterone acetate or norethisterone for 7 to 10 days, from day 15 to 19) was inferior to other medical therapy, including tranexamic acid, danazol and the progestogen‐releasing intrauterine system (Pg‐IUS (off the market since 2001)), releasing 60 mcg of progesterone daily, with respect to reduction of menstrual blood loss (mean difference (MD) 37.29, 95% confidence interval (CI) 17.67 to 56.91; I<sup>2</sup> = 50%; 6 trials, 145 women, low‐quality evidence). The rate of satisfaction and the quality of life with treatment was similar in both groups. The number of bleeding days was greater on the short cycle progestogen group compared to other medical treatments. Adverse events (such as gastrointestinal symptoms and weight gain) were more likely with danazol when compared with progestogen treatment. We note that danazol is no longer in general use for treating HMB. </p> <p>Long‐cycle progestogen therapy (medroxyprogesterone acetate or norethisterone), from day 5 to day 26 of the menstrual cycle, is also inferior compared to the levonorgestrel‐releasing intrauterine system (LNG‐IUS), tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss (MD 16.88, 95% CI 10.93 to 22.84; I<sup>2</sup> = 87%; 4 trials, 355 women, very low‐quality evidence). There was no clear evidence of a difference between progestogen therapy long cycle and other medical therapy in terms of headache (OR 1.45, 95% CI 0.40 to 5.31; I<sup>2</sup> = 0%; 2 trials, 189 women; low‐quality evidence). Breakthrough bleeding or spotting was more likely in women with the LNG‐IUS (OR 0.18, 95% CI 0.06 to 0.55; I<sup>2</sup> = 0%; 3 trials, 220 women; low‐quality evidence). No trials reported on days of bleeding or quality of life for this comparison. </p> <p>The evidence supporting these findings was limited by low or very low gradings of quality; thus, we are uncertain about the findings and there is a potential that they may change if we identify other trials. </p> </section> <section id="CD001016-sec-0007"> <h3 class="title" id="CD001016-sec-0007">Authors' conclusions</h3> <p>Low‐ or very low‐quality evidence suggests that short‐course progestogen was inferior to other medical therapy, including tranexamic acid, danazol and the Pg‐IUS with respect to reduction of menstrual blood loss. Long cycle progestogen therapy (medroxyprogesterone acetate or norethisterone) was also inferior to the LNG‐IUS, tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001016-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001016-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001016-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001016-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001016-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001016-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001016-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD001016-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001016-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001016-abs-0006" lang="en"> <h3>Are cyclical progestogens an effective and safe treatment for heavy menstrual bleeding compared to other medical treatments? </h3> <p><b>Background</b> </p> <p>Heavy menstrual bleeding (HMB) is menstrual bleeding (periods) that interferes with a woman's quality of life, either physical, emotional, social or material, independently of the actual amount of blood loss. Most women with HMB do not have any associated physical cause, such as fibroids, so getting help that does not involve surgery is an attractive alternative. A cyclical progestogen is a hormone tablet that can be taken by mouth for either 10 days or 3 to 4 weeks per month for the treatment of HMB (short or long course cyclical progestogen). </p> <p><b>Trial characteristics</b> </p> <p>This review identified 15 randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with 1071 women in total comparing oral progestogens to other medical treatment for HMB (other oral treatments, intrauterine device and vaginal ring). Our primary outcomes were menstrual blood loss and satisfaction with treatment; the secondary outcomes were number of days of bleeding, quality of life, compliance and acceptability of treatment, adverse events and costs. Evidence is current to January 2019. </p> <p><b>Key results</b> </p> <p>This review of trials found that progestogen hormone tablets taken by mouth for 10 days per month (short course) were less effective at reducing menstrual blood loss when compared to other medical treatments. We are uncertain whether they improved satisfaction or quality of life in women with HMB, or were associated with any difference in adverse effects when compared to other medical treatments. Even though it was less effective at reducing menstrual blood loss, satisfaction with treatment was similar to other medical treatments such as tranexamic acid and Pg‐IUS. </p> <p>We found that progestogen hormone tablets, taken by mouth for three to four weeks from day 5 to 26 of the menstrual cycle (long course), reduced menstrual blood loss but this treatment may be less effective than tranexamic acid, combined hormonal contraceptives and the levonorgestrel‐releasing intrauterine device. No studies in this comparison reported on quality of life. Satisfaction with treatment was similar to women using the combined vaginal ring, but there were no data to compare satisfaction between long cycle and LNG‐IUS or tranexamic acid. There was no evidence of a difference in the occurrence of headache, but long course oral progestogens were associated with a significantly lower incidence of breakthrough bleeding compared with other medical treatment. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence that compared oral progestogens (short and long course) to other medical treatments for HMB was either low or very low which means that we are very uncertain of the findings of the review. The main limitations were risk of bias (women and researchers were aware of the treatment they were receiving which was likely to interfere with the responses, and there was a high number of dropouts from studies) and inconsistency (the results varied among studies). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001016-sec-0215" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001016-sec-0215"></div> <h3 class="title" id="CD001016-sec-0216">Implications for practice</h3> <section id="CD001016-sec-0216"> <p>Progestogens administered from day 15 or 19 to day 26 of the cycle (short cycle) are inferior to other treatment in the treatment of heavy menstrual bleeding (HMB) in women with ovulatory cycles, and offer no advantage over other medical therapies including danazol, tranexamic acid, nonsteroidal anti‐inflammatory drugs (NSAIDs), progestogen‐releasing intrauterine system (Pg‐IUS) and levonorgestrel‐releasing intrauterine system (LNG‐IUS). </p> <p>Oral progestogen therapy for 21 days of the cycle (long cycle) is also inferior to tranexamic acid and the LNG‐IUS but may be similar to the combined vaginal ring. Women find the LNG‐IUS more acceptable than oral progestogen. This regimen of oral progestogen may have a role in the short‐term treatment of HMB. </p> </section> <h3 class="title" id="CD001016-sec-0217">Implications for research</h3> <section id="CD001016-sec-0217"> <p>Quality‐of‐life issues merit further attention since the majority of women complaining of HMB will be offered treatment based on their symptoms alone with no objective measurement of menstrual blood loss. </p> <p>Longer duration of progestogen use, which results in a significant reduction in menstrual blood loss, at present, has been compared with the LNG‐IUS, tranexamic acid and the combined vaginal ring. This merits further assessment against other forms of medical therapy such as NSAIDs and the oral contraceptive pill. </p> <p>Bleeding outcomes were reported in several ways at several time points, affecting the possibility to combine them in meta‐analysis. It is imperative to create CORE outcomes (<a href="./references#CD001016-bbs2-0035" title="KhanK . The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health. British Journal of Obstetrics and Gynaecology2016;123:103‐4. [DOI: 10.1111/1471‐0528.14363] ">Khan 2016</a>), for HMB, in order to be able to compare trials and make strong conclusions and recommendations. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001016-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001016-sec-0036"></div> <div class="table" id="CD001016-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> progestogen therapy, luteal phase only<br/> <b>Comparison:</b> other medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other medical treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen therapy (luteal phase only)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> Assessed with alkaline haematin method </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss ranged from 51 to 97</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 37.29 higher<br/> (17.67 higher to 56.91 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>738 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>693 per 1000<br/> (324 to 915) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.80<br/> (0.17 to 3.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days of bleeding</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of bleeding ranged from 2 to 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.05 days more<br/> (0.69 more to 1.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Physical functioning </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: physical functioning was 14.12</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 lower</p> <p>5.10 lower to 4.24 higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>680 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000<br/> (433 to 731) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.68<br/> (0.36 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> </p> <p>further research is very unlikely to change our confidence in the estimate of effect.</p> <p><b>Moderate quality:</b> </p> <p>further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> </p> <p>further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> </p> <p>we are very uncertain about the estimate.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to moderate heterogeneity.<br/> <sup>b</sup>There are two different luteal phase progestogens, so we downgraded the evidence for this outcome by 1 level.<br/> <sup>c</sup>Downgraded two levels for high risk of detection and attrition bias.<br/> <sup>d</sup>Based only on one trial, downgraded one level.<br/> <sup>e</sup>Downgraded two levels due to high heterogeneity (&gt; 75%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001016-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> progestogen therapy long cycle (3 to 4 weeks)<br/> <b>Comparison:</b> other medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen long cycle (3 to 4 weeks)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> PBAC after 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding PBAC after 3 months ranged from 92‐155</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 16.88 more<br/> (10.93 more to 22.84 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> PBAC after 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding PBAC after 6 months was 80</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 21.42 more<br/> (14.24 more to 28.6 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>708 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>430 per 1000</p> <p>(240 to 633)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.31</p> <p>(0.13 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Days of bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported in any trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of lif</b>e </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported in any trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> <p>Headache</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (18 to 194) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.45<br/> (0.40 to 5.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> <p>Breakthrough bleeding/spotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (14 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.18<br/> (0.06 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; MD: mean difference; <b>OR:</b> Odds ratio; <b>PBAC:</b> Pictorial Blood Assessment Chart; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> </p> <p>further research is very unlikely to change our confidence in the estimate of effect.</p> <p><b>Moderate quality:</b> </p> <p>further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> </p> <p>further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> </p> <p>we are very uncertain about the estimate.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of detection bias. Unknown risk of selection bias. Downgraded one level.<br/> <sup>b</sup>Based only on one trial, downgraded one level.<br/> <sup>c</sup>All the trials had a high risk of detection bias and unknown risk of selection bias. One had high risk of attrition bias. Downgraded two levels. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001016-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001016-sec-0037"></div> <section id="CD001016-sec-0038"> <h3 class="title" id="CD001016-sec-0038">Description of the condition</h3> <p>Heavy menstrual bleeding (HMB), also known as menorrhagia, is an important cause of morbidity in otherwise healthy women. The definition of HMB was considered for a long time as a menstrual blood loss over 80 mL per menstrual cycle; this objective cut‐off was broadly utilized in clinical trials, but such measurement (involving the collection of sanitary pads and tampons and extracting haemoglobin) has proven to be impractical outside research settings. Furthermore, this objectively measured cut‐off of 'heavy' menstrual bleeding may not reflect the woman's experience, nor the impact of the HMB on her quality of life (<a href="./references#CD001016-bbs2-0050" title="WarnerPE , CritchleyHO , LumsdenMA , Campbell‐BrownM , DouglasA , MurrayGD . Menorrhagia II: is the 80mL blood loss criterion useful in management of complaint of menorrhagia?. American Journal of Obstetrics and Gynecology2004;190(5):1224‐9. [DOI: 10.1016/j.ajog.2003.11.016] ">Warner 2004</a>). The Pictorial Blood Assessment Chart (PBAC; <a href="./references#CD001016-bbs2-0034" title="HighamJM , O'BrienPM , ShawRW . Assessment of menstrual blood loss in patients complaining of menorrhagia. British Journal of Obstetrics and Gynaecology1990;97:734‐9. ">Higham 1990</a>), is a semi‐quantitative tool to measure HMB. Currently, the International Federation of Gynaecology and Obstetrics (FIGO) defines HMB focused on the woman's perspective, as "an excessive menstrual blood loss that interferes with the woman's physical, emotional, social, and material quality of life, and can occur alone or in combination with other symptoms" such as dysmenorrhoea, headache or fatigue (<a href="./references#CD001016-bbs2-0042" title="MunroM , CritchleyH , FraserI . The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?. American Journal of Obstetrics and Gynecology2012;207(4):259‐65. [DOI: 10.1016/j.ajog.2012.01.046] ">Munro 2012</a>). </p> <p>In this context, HMB is not related to pregnancy, systemic or gynaecological disease.</p> <p>The prevalence of HMB ranges from 9% to 51%, according to the assessment method, varying from 9% to 15% if measured objectively, to between 20% and 51%, if assessed based on the woman's perception (<a href="./references#CD001016-bbs2-0027" title="FraserI , MansourD , BreymannC , HoffmanC , MezzacasaA , PetragliaF . Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. International Journal of Obstetrics and Gynaecology2015;128(3):196‐200. [DOI: 10.1016/j.ijgo.2014.09.027] ">Fraser 2015</a>; <a href="./references#CD001016-bbs2-0044" title="National Institute for Health and Clinical Excellence (NICE). Heavy Menstrual Bleeding. Clinical Guideline No. 44. National Collaborating Centre for Women’s and Children’s Health Commissioned by the National Institute for Health and Clinical Excellence. www.nice.org.uk/guidance/cg442007. ">NICE 2007</a>; <a href="./references#CD001016-bbs2-0045" title="National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding: assessment and management. National Collaborating Centre for Women’s and Children’s Health Commissioned by the National Institute for Health and Clinical Excellence. www.nice.org.uk/guidance/ng882018. ">NICE 2018</a>). HMB represents a significant clinical challenge and is responsible for up to one‐third of all gynaecological consultations (<a href="./references#CD001016-bbs2-0037" title="LiuZ , DoanQ , BlumenthalP , DuboisR . A systematic review evaluating health‐related quality of life, work impairment, and health‐care costs and utilization in abnormal uterine bleeding. Value in Health Journal2007;10(3):183‐94. [DOI: 10.1111/j.1524‐4733.2007.00168.x] ">Liu 2007</a>; <a href="./references#CD001016-bbs2-0040" title="MillerJ , LenhartG , BonafedeM , BasinskiC , LukesA , TroegerK . Cost effectiveness of endometrial ablation with the NovaSure(R) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives. International Journal of Women's Health2015;7:59‐73. [DOI: 10.2147/ijwh.s75030] ">Miller 2015</a>). </p> </section> <section id="CD001016-sec-0039"> <h3 class="title" id="CD001016-sec-0039">Description of the intervention</h3> <p>Surgery (hysterectomy) was the most common treatment for women with HMB in the UK in the 1980s, with 60% of all secondary care referrals for HMB resulting in hysterectomy (<a href="./references#CD001016-bbs2-0049" title="Van derMeijE , EmanuelM . Hysterectomy for heavy menstrual bleeding. Women's Health (London, England)2016;12(1):63‐9. [DOI: 10.2217/whe.15.87] ">Van der Meij 2016</a>). Currently, hysterectomy is reserved for women for whom other treatment options have failed or are contra‐indicated. </p> <p>A wide variety of medications may be used to reduce HMB. In the UK, norethisterone (norethindrone in the USA) was the most frequently prescribed drug during the 1980s and 1990s, when progestogens constituted 55% of total prescriptions for HMB (<a href="./references#CD001016-bbs2-0024" title="CoulterA , KellandJ , PetoV , ReesMC . Treating menorrhagia in primary care. International Journal of Technology Assessment in Health Care1995;11(3):456‐71. ">Coulter 1995</a>). </p> <p>Prolonged use of high‐dose progestogens is sometimes associated with side effects, including fatigue, mood changes, weight gain, nausea, bloating, oedema, headaches, depression, loss of libido, irregular bleeding, and atherogenic changes in the lipid profile. </p> </section> <section id="CD001016-sec-0040"> <h3 class="title" id="CD001016-sec-0040">How the intervention might work</h3> <p>In the anovulatory woman, progestogens help to co‐ordinate regular uterine shedding when given as a late luteal replacement treatment, on days 19 to 26 of the cycle (<a href="./references#CD001016-bbs2-0023" title="ConynghamRB . Norethisterone in menorrhagia. New Zealand Medical Journal1965;64:697‐701. ">Conyngham 1965</a>). However, the use of progestogens as luteal phase supplementation in the ovulatory woman with HMB is more questionable. Consequently, an increase in the duration and dosage of progestogen therapy was investigated in women with ovulatory HMB. Progesterone is the dominant hormone during the secretory phase of the menstrual cycle and is a potent anti‐inflammatory agent. Progesterone exposure limits endometrial inflammation (<a href="./references#CD001016-bbs2-0039" title="MaybinJA , CritchleyHO . Medical management of heavy menstrual bleeding. Women's Health (London, England)2016;12(1):27‐34. [DOI: 10.2217/whe.15.100] ">Maybin 2016</a>), and long cycle use of progestogens may reduce menstrual bleeding. </p> </section> <section id="CD001016-sec-0041"> <h3 class="title" id="CD001016-sec-0041">Why it is important to do this review</h3> <p>The levonorgestrel intrauterine system (LNG‐IUS) has solid evidence of efficacy in managing HMB (<a href="./references#CD001016-bbs2-0017" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368:128‐37. [CRSREF: 3289371] ">Gupta 2013</a>; <a href="./references#CD001016-bbs2-0046" title="QiuJ , ChengJ , WangQ , HuaJ . Levonogestrel‐releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta‐analysis. Medical Science Monitor2014;20:1700‐13. [DOI: 10.12659/MSM.892126] ">Qiu 2014</a>). Gupta published a randomized controlled trial (RCT) comparing LNG‐IUS with other medical therapies for HMB (<a href="./references#CD001016-bbs2-0017" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368:128‐37. [CRSREF: 3289371] ">Gupta 2013</a>), and Qiu published a systematic analysis including Gupta's results (<a href="./references#CD001016-bbs2-0046" title="QiuJ , ChengJ , WangQ , HuaJ . Levonogestrel‐releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta‐analysis. Medical Science Monitor2014;20:1700‐13. [DOI: 10.12659/MSM.892126] ">Qiu 2014</a>). Both authors concluded that LNG‐IUS is more effective for the treatment of HMB than oral medical treatment. However, for women who wish to avoid an intrauterine device, or for whom such a device is contra‐indicated, other medical treatments may have a role. The role and efficacy of oral progestogens in treating HMB remains controversial and the objective of this review is to address this issue. </p> <p>This is the update of a Cochrane review last updated in 2007, originally named "Effectiveness of cyclical progestagen therapy in reducing heavy menstrual bleeding" (<a href="./references#CD001016-bbs2-0052" title="LethabyA , IrvineGA , CameronIT . Cyclical progestogens for heavy menstrual bleeding. Cochrane Database of Systematic Reviews1998, Issue 4. [DOI: 10.1002/14651858.CD001016] ">Lethaby 1998b</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001016-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001016-sec-0042"></div> <p>To determine the effectiveness, safety and tolerability of oral progestogen therapy taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), in achieving a reduction in menstrual blood loss in women of reproductive age with HMB. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001016-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001016-sec-0043"></div> <section id="CD001016-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001016-sec-0045"> <h4 class="title">Types of studies</h4> <p> <ol id="CD001016-list-0001"> <li> <p>All RCTs comparing oral progestogen therapies, taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), when used to reduce HMB versus placebo. </p> </li> <li> <p>All RCTs comparing oral progestogen therapies, taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), versus other medical therapies when used to reduce HMB. </p> </li> </ol> </p> </section> <section id="CD001016-sec-0046"> <h4 class="title">Types of participants</h4> <p> <ol id="CD001016-list-0002"> <li> <p>Women of reproductive age</p> </li> <li> <p>Women with regular heavy periods measured either subjectively by the woman, objectively by the alkaline haematin method (more than 80 mL per cycle) or semi‐objectively by the pictorial blood assessment chart (<a href="./references#CD001016-bbs2-0029" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. ">Hallberg 1964</a>; <a href="./references#CD001016-bbs2-0034" title="HighamJM , O'BrienPM , ShawRW . Assessment of menstrual blood loss in patients complaining of menorrhagia. British Journal of Obstetrics and Gynaecology1990;97:734‐9. ">Higham 1990</a>; <a href="./references#CD001016-bbs2-0043" title="NewtonJ , BarnardG , CollinsW . A rapid method for measuring menstrual blood loss using automatic extraction. Contraception1977;16:269‐82. ">Newton 1977</a>). </p> </li> <li> <p>Women attending primary care, family planning or specialist clinics</p> </li> </ol> </p> <p>Exclusion criteria</p> <p> <ol id="CD001016-list-0003"> <li> <p>Post‐menopausal bleeding (more than one year following the last period)</p> </li> <li> <p>Irregular menses and intermenstrual bleeding</p> </li> <li> <p>Pathological causes of HMB</p> </li> <li> <p>Iatrogenic causes of HMB</p> </li> </ol> </p> </section> <section id="CD001016-sec-0047"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD001016-list-0004"> <li> <p>Oral progestogen therapy (norethisterone, dydrogesterone, medroxyprogesterone acetate) versus placebo </p> </li> <li> <p>Oral progestogen therapy versus any other medical therapy: antifibrinolytic agents, danazol, non‐steroidal anti‐inflammatory drugs (NSAIDs), gonadotrophin‐releasing hormone analogues, combined hormonal contraceptives (oral or vaginal ring), selective oestrogen receptor modulators (SERMs), progestogen‐releasing intrauterine systems (Pg‐IUS) and levonorgestrel‐releasing intrauterine device (LNG‐IUS). </p> </li> </ol> </p> <p>We considered variable doses and lengths of administration of treatments. Oral progestogens can be given as luteal phase replacement treatment (for 7 to 10 days from day 15 or day 19 of the menstrual cycle) or as a longer course of 21 out of 28 days (days 5 to 26 of the cycle). </p> </section> <section id="CD001016-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>Where available, we recorded the following outcomes.</p> <section id="CD001016-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001016-list-0005"> <li> <p>Menstrual blood loss</p> <ol id="CD001016-list-0006"> <li> <p>Objective assessment of blood loss, either during the intervention or for up to one year of follow‐up after the intervention, measured by the alkaline haematin method (<a href="./references#CD001016-bbs2-0029" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. ">Hallberg 1964</a>), or the pictorial blood assessment chart (<a href="./references#CD001016-bbs2-0034" title="HighamJM , O'BrienPM , ShawRW . Assessment of menstrual blood loss in patients complaining of menorrhagia. British Journal of Obstetrics and Gynaecology1990;97:734‐9. ">Higham 1990</a>) </p> </li> <li> <p>Subjective (woman's perception) assessment of blood loss, also measured either during the intervention or for up to one year of follow‐up after the intervention. </p> </li> </ol> </li> <li> <p>Satisfaction: overall satisfaction with treatment.</p> </li> </ol> </p> </section> <section id="CD001016-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001016-list-0007"> <li> <p>Number of days bleeding during the intervention menstrual cycle</p> </li> <li> <p>Quality of life: women's perceived change in quality of life, provided this was recorded in a reproducible and validated format </p> </li> <li> <p>Compliance with treatment</p> </li> <li> <p>Acceptability of treatment</p> </li> <li> <p>Adverse events, of any degree, reported either spontaneously by the woman or elicited from specific questioning </p> </li> <li> <p>Resource use and cost</p> </li> </ol> </p> </section> </section> </section> <section id="CD001016-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs of cyclical progestogens for the treatment of HMB, without language restriction and in consultation with the Cochrane Gynaecology and Fertility (CGF) Information Specialist. </p> <section id="CD001016-sec-0052"> <h4 class="title">Electronic searches</h4> <p>For the update of this review in 2019, we searched the Cochrane Gynaecology and Fertility Register of controlled trials (searched January 2019; Procite platform), the Cochrane Central Register of Studies (CRSO), MEDLINE (searched from 1946 to January 2019) via Ovid, Embase (searched from 1980 to January 2019) via Ovid, PsycINFO (searched from 1806 to January 2019) via Ovid, and CINAHL (searched from 1961 to January 2019) via Ebsco. See <a href="./appendices#CD001016-sec-0221">Appendix 1</a>; <a href="./appendices#CD001016-sec-0222">Appendix 2</a>; <a href="./appendices#CD001016-sec-0223">Appendix 3</a>; <a href="./appendices#CD001016-sec-0224">Appendix 4</a>; <a href="./appendices#CD001016-sec-0225">Appendix 5</a>; <a href="./appendices#CD001016-sec-0226">Appendix 6</a>. </p> <p>We also searched citation lists of included trials and relevant review articles. For most of the included trials, we contacted the first author to clarify issues relating to data extraction. </p> </section> <section id="CD001016-sec-0053"> <h4 class="title">Searching other resources</h4> <p>Trials registers for ongoing and registered trials:</p> <p> <ol id="CD001016-list-0008"> <li> <p><a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> (a service of the US National Institutes of Health) (January 2019) </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a> (World Health Organization International Trials Registry Platform search portal). (January 2019) </p> </li> </ol> </p> </section> </section> <section id="CD001016-sec-0054"> <h3 class="title" id="CD001016-sec-0054">Data collection and analysis</h3> <p>We conducted data collection and analysis in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001016-bbs2-0030" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). </p> <section id="CD001016-sec-0055"> <h4 class="title">Selection of studies</h4> <p>For the 2019 update, Marian Showell (CGF Information Specialist) conducted the initial search. MB and CL conducted an initial screen of titles and abstracts using <a href="./references#CD001016-bbs2-0025" title="Veritas Health Innovation. Covidence. Version accessed January 2019. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>, and then we retrieved the full texts of all potentially eligible trials. Two review authors (MB and AL) independently examined these full‐text articles for compliance with the inclusion criteria and selected eligible trials. We resolved disagreements by discussion. If any reports required translation, we described the process used for data collection. We documented the selection process with a PRISMA flow chart (<a href="./references#CD001016-bbs2-0041" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>; <a href="#CD001016-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD001016-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram" data-id="CD001016-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> </div> </section> <section id="CD001016-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>In the 2019 update, two review authors (MB and AL) independently performed the data extraction from three trials (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), using forms designed according to Cochrane guidelines (<a href="./references#CD001016-bbs2-0031" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011b</a>). The remaining five new trials (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), were already included in other Cochrane Reviews of treatments for HMB. We obtained data from those reviews. </p> <p>In the previous versions of the review two authors (AL and GI) performed the screening, data extraction and risk of bias assessment. </p> <p>We analysed included trials for the following criteria and methodological details.</p> <section id="CD001016-sec-0057"> <h5 class="title">Trial characteristics</h5> <p> <ol id="CD001016-list-0009"> <li> <p>Method of randomization</p> </li> <li> <p>Presence or absence of blinding to treatment allocation</p> </li> <li> <p>Quality of allocation concealment</p> </li> <li> <p>Number of women randomized, excluded or lost to follow‐up</p> </li> <li> <p>Whether an intention‐to‐treat analysis was done</p> </li> <li> <p>Whether a power calculation was done</p> </li> <li> <p>Duration, timing and location of the trial</p> </li> <li> <p>Source of funding</p> </li> <li> <p>Conflict of interest</p> </li> </ol> </p> </section> <section id="CD001016-sec-0058"> <h5 class="title">Characteristics of the women in the trial</h5> <p> <ol id="CD001016-list-0010"> <li> <p>Age and any other recorded characteristics of women in the trial</p> </li> <li> <p>Methods used to define HMB</p> </li> <li> <p>Other inclusion criteria</p> </li> <li> <p>Exclusion criteria</p> </li> </ol> </p> </section> <section id="CD001016-sec-0059"> <h5 class="title">Interventions used</h5> <p> <ol id="CD001016-list-0011"> <li> <p>Types of medical therapy used</p> </li> <li> <p>Dose, duration and timing of administration of medical therapy</p> </li> </ol> </p> </section> <section id="CD001016-sec-0060"> <h5 class="title">Outcomes</h5> <p> <ol id="CD001016-list-0012"> <li> <p>Methods used to measure menstrual blood loss at or after intervention</p> </li> <li> <p>Methods used to evaluate patient satisfaction, symptoms and change in quality of life</p> </li> </ol> </p> <p>Two review authors (MB and AL) independently assessed the quality of the included trials. Where necessary, we sought additional information on trial methodology or actual trial data from the principal author of any trial that appeared to meet the eligibility criteria. In cases where trials presented results in graphs and did not give any actual data, we extracted the data from the graphs. </p> </section> </section> <section id="CD001016-sec-0061"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MB and AL) independently assessed the included trials for risk of bias using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD001016-bbs2-0032" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. [PUBMED: 22008217] ">Higgins 2011c</a>; <a href="./references#CD001016-bbs2-0033" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). Individual domains included sequence generation, allocation concealment, blinding and incomplete outcome data; we scored each domain separately as either low, unclear or high risk of bias for three new trials (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). For the remaining five new trials (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>) that were previously included in other Cochrane Reviews of treatments for HMB, we extracted risk of bias from the reviews. </p> <p>This assessment is presented in 'Risk of bias' tables in the <a href="./references#CD001016-sec-0237" title="">Characteristics of included studies</a> and summary figures (<a href="#CD001016-fig-0002">Figure 2</a>; <a href="#CD001016-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001016-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials" data-id="CD001016-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials </p> </div> </div> </div> <div class="figure" id="CD001016-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial" data-id="CD001016-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial </p> </div> </div> </div> <p>In the previous version of the review two authors (from AL, GI or IC) assessed risk of bias. </p> </section> <section id="CD001016-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (for example proportion of women who found the treatment unacceptable), we expressed results for each trial as an odds ratio (OR) with 95% confidence intervals (CI) and combined them for meta‐analysis with Review Manager 5 (RevMan 5) software using the Peto‐modified Mantel‐Haenszel method (<a href="./references#CD001016-bbs2-0047" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>We encountered difficulties with the reporting of continuous outcomes (for example menstrual blood loss after treatment). Meta‐analysis with RevMan 5 software uses a mean difference (MD) to combine outcomes and requires data to be presented as absolute values of post‐treatment means with their standard deviations (SD). For some outcomes, particularly menstrual blood loss, the data are skewed and trial authors correctly presented their data as medians with a range. Where possible, we obtained original data from the principal trial authors but post‐treatment means and standard deviations were not always either available or calculable. Where only medians and ranges were available, we regarded the median as being identical to the mean and we calculated a crude estimate of the SD from the range ((range x 0.95)/4). This method is not ideal for skewed data and is likely to result in an over‐estimation of the SD but we had planned a priori to perform sensitivity analysis with and without these trials included in the meta‐analysis. Without exception, the distribution of data on menstrual blood loss are usually skewed and the ideal and most appropriate statistical analysis is nonparametric rather than by inclusion in a meta‐analysis assessing a mean difference. </p> </section> <section id="CD001016-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>We undertook all analyses per woman randomized. Participants were individually randomized to the groups and a single measurement for each outcome from each participant was collected and analysed. </p> </section> <section id="CD001016-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat basis as far as possible (i.e. including all randomized participants in analysis, in the groups to which they were randomized). We attempted to obtain missing data from the original trial authors (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). Where these were unobtainable, we undertook imputation of individual values for primary outcomes only. For other outcomes, we analysed only the available data (<a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). </p> </section> <section id="CD001016-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included trials were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I² statistic. If the I² statistic measurement was greater than 50%, we took this as an indication of substantial heterogeneity (<a href="./references#CD001016-bbs2-0026" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD001016-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>To minimize the potential impact of the difficulty of detecting and correcting for publication bias and other reporting biases, we ensured a comprehensive search for eligible trials, and were alert for duplication of data. If there were 10 or more trials in an analysis, we planned to use a funnel plot to explore the possibility of small‐trial effects (a tendency for estimates of the intervention effect to be more beneficial in smaller trials; <a href="./references#CD001016-bbs2-0048" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). </p> </section> <section id="CD001016-sec-0067"> <h4 class="title">Data synthesis</h4> <p>If the trials were sufficiently similar, we combined the data using a fixed‐effect model in the following comparisons: </p> <p> <ol id="CD001016-list-0013"> <li> <p>Progestogen versus placebo</p> </li> <li> <p>Progestogen therapy (luteal phase only) versus NSAIDs</p> </li> <li> <p>Progestogen therapy (luteal phase only) versus danazol</p> </li> <li> <p>Progestogen therapy (luteal phase only) versus tranexamic acid</p> </li> <li> <p>Progestogen therapy (norethisterone luteal phase only) versus progestogen‐releasing IUS: Pg‐IUS and LNG‐IUS </p> </li> <li> <p>Progestogen therapy (medroxyprogesterone acetate luteal phase only) versus LNG‐IUS</p> </li> <li> <p>Progestogen therapy (3‐4 weeks) versus LNG‐IUS</p> </li> <li> <p>Progestogen therapy (3‐4 weeks) versus tranexamic acid</p> </li> <li> <p>Progestogen therapy (3‐4 weeks) versus combined hormonal vaginal ring</p> </li> <li> <p>Progestogen therapy (3‐4 weeks) versus ormeloxifene</p> </li> <li> <p>Overall comparison: progestogen therapy (luteal phase only) versus other medical therapy</p> </li> <li> <p>Overall comparison: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy </p> </li> </ol> </p> </section> <section id="CD001016-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We assessed differences between the action of luteal phase progestogen and long‐cycle (i.e. 3 to 4 weeks) progestogen. There was no substantial heterogeneity. </p> </section> <section id="CD001016-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analysis to compare potential differences in participants, interventions, outcomes and whether allocation concealment was adequate in the included trials. We could not undertake any sensitivity analysis because of the small numbers of included trials for each outcome. </p> <section id="CD001016-sec-0070"> <h5 class="title">Overall quality of the body of evidence</h5> <p>We generated 'Summary of findings' tables using GRADEpro GDT software (<a href="./references#CD001016-bbs2-0028" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 4 December 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>), to evaluate the overall quality of the body of evidence for the two overall comparisons: luteal phase and long‐cycle progestogen versus other medical therapy, for the following outcomes: menstrual blood loss; satisfaction; menstruation days; quality of life; and adverse effects. Two review authors (MBR and AL) made independent judgments on the overall quality of trials for each of these outcomes, according to the GRADE criteria (trial limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). For each GRADE criterion, if there were concerns about quality, the assessment could be downgraded either one or two levels. Overall quality for each outcome could be categorized as either high, moderate, low or very low, according to these assessments. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001016-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001016-sec-0071"></div> <section id="CD001016-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD001016-sec-0073"> <h4 class="title">Results of the search</h4> <p>We included seven RCTs of oral progestogen therapy for regular HMB in the 2007 version of the review. </p> <p>We considered a further 11 potential trials eligible for the 2019 update and retrieved the full texts of the papers (when available) for closer inspection. We included eight new trials (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). There were no trials awaiting classification; we excluded three trials (<a href="./references#CD001016-bbs2-0017" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368:128‐37. [CRSREF: 3289371] ">Gupta 2013</a>; <a href="./references#CD001016-bbs2-0018" title="KarakusS , KiranG , CiralikH . Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Australian and New Zealand Journal of Obstetetrics and Gynaecology2009;49(6):685‐8. [DOI: 10.1111/j.1479‐828X.2009.01093.x.] ">Karakus 2009</a>; <a href="./references#CD001016-bbs2-0019" title="KucukU , ErtanK . Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomised prospective controlled trial in female smokers. Clinical Experimental Obstetrics and Gynecology2008;35(1):57‐60. [CRSREF: 3289436] ">Kucuk 2008</a>), and there was one ongoing trial (<a href="./references#CD001016-bbs2-0020" title="Combined oral contraceptives, progestogens, and non‐steroidal anti‐inflammatory drugs for heavy and/or prolonged menstrual bleeding without organic cause. Ongoing study2016. ">NCT02943655</a>), comparing the combined contraceptive pill, medroxyprogesterone acetate and mefenamic acid. </p> <p>Thus, we included a total of 15 RCTs of oral progestogen therapy for regular HMB in the review. Summary details of the trials are given in the <a href="./references#CD001016-sec-0237" title="">Characteristics of included studies</a>. </p> </section> <section id="CD001016-sec-0074"> <h4 class="title">Included studies</h4> <p>Noresthisterone and medroxyprogesterone acetate were the only two types of oral progestogen included in trials for the treatment of HMB. </p> <section id="CD001016-sec-0075"> <h5 class="title">Design and setting</h5> <p>All 15 included RCTs have a parallel‐group design.</p> <p>Eleven trials were single‐centre trials; the country settings included Egypt, India, Iran, Ireland, Turkey, and UK. Three trials recruited participants from various sites across individual countries: Pakistan (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>), Iran (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>), and China (<a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), and one trial was multicentre based in Brazil, Canada and USA (<a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>). </p> </section> <section id="CD001016-sec-0076"> <h5 class="title">Time frame</h5> <p>Six trials reported their recruiting time frame, three between 2002 and 2008 (<a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), and five between 2008 and 2014 (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). The remaining trials did not report their recruiting time and were all published prior to 1999 (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>). </p> </section> <section id="CD001016-sec-0077"> <h5 class="title">Participants</h5> <p>The 15 included trials contained 1071 participants with age ranging mostly between 25 and 40 years. </p> <p>All the trials but one <b>(</b><a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), stated that inclusion criteria required a normal uterus and no associated pathology. </p> <p>Three trials mentioned weight as a characteristic of women: one included only women with a body mass index (BMI) between 19 and 29 (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>), one excluded women with a BMI over 35 (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>), and one excluded women who weighed over 110 kg (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>). </p> </section> <section id="CD001016-sec-0078"> <h5 class="title">Interventions</h5> <p>There were only two different oral progestogens included in the trials: norethisterone and medroxyprogesterone acetate, used either as luteal phase (for 10 to 14 days from day 14 of the menstrual cycle) or long cycle (3 to 4 weeks from day 2 to 5 of the cycle). </p> <p>Nine RCTs (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), with a total of 355 women, assessed the effects of oral progestogen therapy administered during the luteal phase of the menstrual cycle (starting between days 15 or 19 and finishing between days 23 and 26 of the menstrual cycle). Three of these compared norethisterone with danazol (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>); one with mefenamic acid (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>); three with tranexamic acid (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>); and one trial with small numbers (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>) compared norethisterone with danazol, mefenamic acid and a Pg‐IUS (Progestasert). One of the danazol trials compared norethisterone with two separate danazol groups (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>): a continuous regimen of 200 mg a day for three cycles and a reducing regimen of 200 mg a day for the first cycle, 100 mg a day during the next cycle and 50 mg a day during the last cycle. One trial (<a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>), compared medroxyprogesterone acetate during the luteal phase to the LNG‐IUS. One trial compared short cycle norethisterone with tranexamic acid and LNG‐IUS (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>). </p> <p>Six RCTs (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), with a total of 487 women, assessed the effects of oral progestogen therapy administered from day three to five of the menstrual cycle for 21 to 25 days. Three used norethisterone 5 mg three times a day from day 5 to 26 (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>), and three used medroxyprogesterone acetate 10 mg to 20 mg a day for 21 days a month (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). Two compared a regimen of three to four weeks of oral progestogen to the LNG‐IUS (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>), two to tranexamic acid (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>), one to the combined vaginal ring (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>), and one to ormeloxifene (<a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). </p> </section> <section id="CD001016-sec-0079"> <h5 class="title">Comparisons</h5> <p>None of the included trials compared cyclical progestogen to placebo.</p> <p>Twelve trials assessed luteal phase progestogen.</p> <p> <ol id="CD001016-list-0014"> <li> <p>Two compared luteal norethisterone to NSAIDs (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>) </p> </li> <li> <p>Four compared luteal norethisterone to danazol (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>) </p> </li> <li> <p>Three compared luteal norethisterone to tranexamic acid (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>) </p> </li> <li> <p>Two compared luteal norethisterone to progestogen‐releasing intrauterine devices, one releasing 65 mcg progestogen daily (Pg‐IUS; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), and one releasing 20 mcg of levonorgestrel daily (LNG‐IUS; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>). </p> </li> <li> <p>One compared luteal medroxyprogesterone acetate to Pg‐IUS (<a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>) </p> </li> </ol> </p> <p>Six trials compared long cycle oral progestogens.</p> <p> <ol id="CD001016-list-0015"> <li> <p>Two trials compared long cycle norethisterone to LNG‐IUS (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>), both using the intrauterine system releasing 20 mcg levonorgestrel daily </p> </li> <li> <p>Two trials compared long cycle medroxyprogesterone acetate to tranexamic acid (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>) </p> </li> <li> <p>One trial compared long cycle norethisterone to the combined vaginal ring (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>) </p> </li> <li> <p>One trial compared long cycle medroxyprogesterone acetate to ormeloxifene (<a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>) </p> </li> </ol> </p> <p>Two of the trials were multi‐arm.</p> <p> <ol id="CD001016-list-0016"> <li> <p>One with four arms (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), compared luteal norethisterone, danazol, NSAIDs and Pg‐IUS </p> </li> <li> <p>One with three arms (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), compared long cycle norethisterone, tranexamic acid and LNG‐IUS </p> </li> </ol> </p> </section> <section id="CD001016-sec-0080"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0081"> <h6 class="title">Menstrual blood loss</h6> <p>Thirteen trials measured bleeding as an outcome.</p> <p>Only 13 trials reported bleeding. The criteria for HMB varied among trials: blood loss over 80 mL per cycle in four trials (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>); and blood loss over 50 mL per cycle in one trial (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>). Five trials used the Pictorial Blood Assessment Chart (PBAC): two used a cut off over 100 for two cycles<b>(</b><a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), and one for two cycles over 185 (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>). Two used only one cycle: one trial used PBAC over 100 (<a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>) and one used PBAC over 130 (<a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). One trial used a subjective assessment of menstrual blood loss, using a modified PBAC (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>). One trial used the clinical history of excessive menstrual loss proving socially and domestically disruptive associated with anaemia (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>), and one trial, the use of more than three pads a day (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>). Five trials assessed menstrual blood loss using the alkaline haematin method (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>): one recorded amenorrhoea (<a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>); and one the woman's perception of improvement of bleeding (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>). Four trials reported haemoglobin (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>), and one of them also reported ferritin levels (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>). </p> </section> <section id="CD001016-sec-0082"> <h6 class="title">Satisfaction</h6> <p>Three trials reported overall satisfaction (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>). This was added as an outcome at the 2019 update. </p> </section> </section> <section id="CD001016-sec-0083"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001016-list-0017"> <li> <p>Eight trials reported the number of days of menstrual bleeding (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>) </p> </li> <li> <p>Quality of life was reported in six trials, using different approaches: two did not specify which questionnaire of quality of life was used (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), one used the HRQoL‐4 (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>), one the World Health Organization QoL‐Short Form (Turkish version) (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), one the SF‐36 QoL ( <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>); and one asked women how their periods interfered with their quality of life both before and after treatment (<a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>). </p> </li> <li> <p>Patient compliance with the treatment was reported by two trials (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>). </p> </li> <li> <p>Two trials reported the acceptability of treatment (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>). </p> </li> <li> <p>The prevalence of side effects of any degree, reported either spontaneously by the woman or elicited from specific questioning, was reported in nine trials (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>). </p> </li> <li> <p>Resource use and cost: no trial reported this outcome.</p> </li> </ol> </p> </section> </section> <section id="CD001016-sec-0084"> <h4 class="title">Excluded studies</h4> <p>We excluded four trials.</p> <p> <ul id="CD001016-list-0018"> <li> <p><a href="./references#CD001016-bbs2-0016" title="AzizkhaniM , Vahid DastjerdiM , Tabaraee AraniM , PirjaniR , SepidarkishM , GhoratF , et al. Traditional dry cupping therapy versus medroxyprogesterone acetate in the treatment of idiopathic menorrhagia: a randomized controlled trial. Iranian Red Crescent Medical Journal2018;20(2):e60508. [: 10.5812/ircmj.60508] ">Azizkhani 2018</a>: the comparison was an alternative treatment (traditional dry cupping). </p> </li> <li> <p><a href="./references#CD001016-bbs2-0017" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368:128‐37. [CRSREF: 3289371] ">Gupta 2013</a>: the randomization was LNG‐IUS versus any other medical treatment, the choice of which medical treatment was according to the woman's preference. The comparison was a variety of different types of other medical treatment and there were no data specifically for cyclical progestogen (even though it was one of the comparators). </p> </li> <li> <p><a href="./references#CD001016-bbs2-0018" title="KarakusS , KiranG , CiralikH . Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. Australian and New Zealand Journal of Obstetetrics and Gynaecology2009;49(6):685‐8. [DOI: 10.1111/j.1479‐828X.2009.01093.x.] ">Karakus 2009</a>: the population was women with irregular bleeding. </p> </li> <li> <p><a href="./references#CD001016-bbs2-0019" title="KucukU , ErtanK . Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomised prospective controlled trial in female smokers. Clinical Experimental Obstetrics and Gynecology2008;35(1):57‐60. [CRSREF: 3289436] ">Kucuk 2008</a>: this is a quasi‐randomized trial. </p> </li> </ul> </p> </section> </section> <section id="CD001016-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD001016-sec-0086"> <h4 class="title">Allocation</h4> <p>The random sequence generation received a low risk score for the majority of the trials (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). Three received an unclear risk because they did not clearly state their randomization technique (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>), and one had high risk of bias because they used a sequential order for randomization (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>). </p> <p>Eight trials had an unclear risk of bias for allocation (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), mostly because they did not clearly state their allocation method. Seven trials received a low risk score for allocation based on adequate concealment prior to randomization (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). However, one of these trials (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>), had a very high dropout rate (more than 50%) after randomization. In this trial, 103 women were randomized to two parallel groups, either norethisterone or tranexamic acid, and proceeded to take placebo medication for two menstrual cycles. Fifty‐seven of the participants (55%) were then excluded from the treatment phase because the measured menstrual blood loss was less than 80 mL per cycle, there was poor compliance or lack of ovulation. </p> </section> <section id="CD001016-sec-0087"> <h4 class="title">Blinding</h4> <section id="CD001016-sec-0088"> <h5 class="title">Performance bias</h5> <p>Only two trials were double‐blinded and scored as at low risk of performance bias (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), for objective and subjective outcomes. The remaining trials (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>) scored at high risk for performance bias of subjective outcomes, as the lack of blinding was likely to influence the outcomes. For the objective outcome (alkaline haematin) six trials scored at low risk (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), as the lack of blinding was unlikely to influence the outcome. We were obliged to score seven trials as unclear for performance bias of objective outcomes, as they did not report alkaline haematin (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). </p> </section> <section id="CD001016-sec-0089"> <h5 class="title">Detection bias</h5> <p>Two of the trials scored at low risk for detection bias of objective and subjective outcomes (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), both were double‐blind, placebo‐controlled trials. Of the remaining trials, for subjective outcomes two scored as unclear, one because it was single‐blinded and placebo controlled (likely to have blinded the participants; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>), and the other because it was unclear whether or not personnel were blinded (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>). Eleven trials scored at high risk for detection bias (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), as the lack of blinding was likely to influence the outcomes. For the objective outcome, we scored the detection bias of six trials as low (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), because the blinding (presence or absence) was unlikely to influence the outcome. The remaining nine trials did not report alkaline haematin so we were obliged to score them as unclear (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). </p> </section> </section> <section id="CD001016-sec-0090"> <h4 class="title">Incomplete outcome data</h4> <p>Four trials were scored as at high risk of attrition bias; one for 20% lost after randomization and further 26% during treatment (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>), the other three for substantial dropouts or loss to follow up (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>). </p> <p>Four trials scored as at unclear risk of attrition bias; one because no withdrawals or exclusions were reported (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>), one for significant loss to follow‐up, but with similar numbers and reasons for each group (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>) and one because authors stated that they performed both ITT and per protocol analyses but it appears that this was only for two outcomes (<a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>) and one trial excluded 55% after randomization (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>). </p> <p>The remaining seven trials scored at low risk of attrition bias (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). </p> </section> <section id="CD001016-sec-0091"> <h4 class="title">Selective reporting</h4> <p>We scored eight trials as at unclear risk of selective reporting. Most of these took place before 1996 and did not have a registered protocol (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>). We scored five trials as at low risk of reporting bias, because they reported all their previously stated outcomes in the results (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>). We scored two trials as at high risk for reporting bias (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>); <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a> because the protocol in the trial register reported fewer outcomes than those reported in the publication, and <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a> because the trial authors only reported significant results in the abstract, which appears to favour the experimental treatment. Quality‐of‐life scores after one month were significantly improved after one cycle of treatment in the experimental group, but after two cycles of treatment and at follow‐up the scores were similar. <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a> did not report this finding, which suggests that the conclusions were influenced by lack of reporting. </p> <p>The authors of two trials provided original data. In one case, we calculated means and SDs from the data provided by the trial author, since they only reported medians and ranges in the publication (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>). Extra data from the other trial allowed us to assess additional outcomes not reported in the publication (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>). </p> </section> <section id="CD001016-sec-0092"> <h4 class="title">Other potential sources of bias</h4> <section id="CD001016-sec-0093"> <h5 class="title">Baseline</h5> <p>Almost all trials had similar baseline groups. We only scored one trial as unclear because it had no clear indication that the groups were similar at baseline (<a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>) and one as high risk because of substantial imbalance at baseline (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>). </p> </section> <section id="CD001016-sec-0094"> <h5 class="title">Funding</h5> <p>Two trials were funded by University Grants (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>), one by a Birthright Research Grant from the Royal College of Obstetricians &amp; Gynaecologists (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), and one by the Indian Council of Medical Research (<a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>). Six trials received funding from drug companies (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). One trial denied receiving any funding (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>). Three trials did not state any funding source (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), and one trial that did not state funding declared that the treatment was provided by a drug company and the sanitary pads were supplied by Industry (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>). </p> </section> <section id="CD001016-sec-0095"> <h5 class="title">Conflict of interest</h5> <p>Only two trials clearly reported not having any conflicts of interest (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>). The remaining thirteen studies did not state whether they had any conflicts of interest. </p> <p>The risk of bias for other potential source of bias was reported according to the 3 criteria above. One trial was scored as high risk of bias for substantial imbalance at baseline in menstrual bleeding (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>). Four trials were scored as unclear as no details were provided for the other potential sources (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>;<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>; <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>) and one had different age groups at baseline and was funded by a drug company (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>). The remaining ten trials scored low risk of other potential sources of bias (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>; <a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>; <a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>) </p> </section> </section> </section> <section id="CD001016-sec-0096"> <h3 class="title" id="CD001016-sec-0096">Effects of interventions</h3> <p>See: <a href="./full#CD001016-tbl-0001"><b>Summary of findings for the main comparison</b> Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</a>; <a href="./full#CD001016-tbl-0002"><b>Summary of findings 2</b> Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</a> </p> <section id="CD001016-sec-0097"> <h4 class="title">1. Oral progestogen therapy versus placebo</h4> <p>No included trials compared placebo to cyclical progestogen.</p> </section> <section id="CD001016-sec-0098"> <h4 class="title">2. Progestogen therapy (luteal phase only) versus non‐steroidal anti‐inflammatory drugs (NSAIDs) </h4> <p>Two trials with a total of 177 women compared luteal phase norethisterone versus NSAIDs (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>). </p> <section id="CD001016-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0100"> <h6 class="title">2.1 Menstrual blood loss</h6> <p>There was no clear evidence of difference in the menstrual blood loss measured by the alkaline haematin method between luteal phase norethisterone and NSAIDs in either trial (MD 22.97, 95% CI −0.62 to 46.57; I<sup>2</sup> = 71%; 2 trials; 48 women; <a href="./references#CD001016-fig-0005" title="">Analysis 2.1</a>; <a href="#CD001016-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001016-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 12: Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, outcome: 12.1 Bleeding PBAC after 3 months." data-id="CD001016-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 12: Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, outcome: 12.1 Bleeding PBAC after 3 months. </p> </div> </div> </div> </section> <section id="CD001016-sec-0101"> <h6 class="title">2.2 Satisfaction</h6> <p>Neither trial reported data on the women's satisfaction with the treatment.</p> </section> </section> <section id="CD001016-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0103"> <h6 class="title">2.3 Days of bleeding</h6> <p>The number of days of bleeding during the intervention menstrual cycle did not report a clear difference between the norethisterone and NSAIDs groups (MD 0.41, 95% CI −0.13 to 0.95; I<sup>2</sup> = 35%; 2 trials, 48 women; <a href="./references#CD001016-fig-0006" title="">Analysis 2.2</a>). </p> </section> <section id="CD001016-sec-0104"> <h6 class="title">2.4 Quality of life</h6> <p>No trials reported data on changes in the quality of life with treatment.</p> </section> <section id="CD001016-sec-0105"> <h6 class="title">2.5 Compliance</h6> <p>One trial (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>), did not report clear evidence of a difference between the luteal phase norethisterone and NSAIDs in women's compliance with treatment (Peto OR 0.88, 95% CI 0.05 to 14.78; 1 trial, 32 women; <a href="./references#CD001016-fig-0007" title="">Analysis 2.3</a>). </p> </section> <section id="CD001016-sec-0106"> <h6 class="title">2.6 Acceptability</h6> <p>Neither of the trials reported data on the acceptability of the treatment for this comparison. </p> </section> <section id="CD001016-sec-0107"> <h6 class="title">2.7 Adverse events</h6> <p>One trial (<a href="./references#CD001016-bbs2-0005" title="CameronIT , HainingR , LumsdenMA , ThomasVR , SmithSK . The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology1990;76:85‐8. SmithS , HainingR , Reed‐ThomasV , CameronI . The diagnosis and treatment of menorrhagia (abstract). Silver Jubilee British Congress of Obstetrics and Gynaecology1989:62. ">Cameron 1990</a>), reported adverse events, of any degree, reported either spontaneously by the woman or elicited from specific questioning. There was no clear evidence of difference between luteal phase norethisterone and NSAIDs in: </p> <p> <ol id="CD001016-list-0019"> <li> <p>total adverse events (Peto OR 1.86, 95% CI 0.44 to 7.86; 1 trial, 32 women; <a href="./references#CD001016-fig-0008" title="">Analysis 2.4</a>); </p> </li> <li> <p>headache (Peto OR 1.60, 95% CI 0.35 to 7.31; 1 trial, 32 women; <a href="./references#CD001016-fig-0009" title="">Analysis 2.5</a>); </p> </li> <li> <p>gastrointestinal symptoms (Peto OR 0.56, 95% CI 0.05 to 5.83; 1 trial, 32 women; <a href="./references#CD001016-fig-0010" title="">Analysis 2.6</a>); </p> </li> <li> <p>dysmenorrhoea (Peto OR 1.16, 95% CI 0.20 to 6.69; 1 trial, 32 women; <a href="./references#CD001016-fig-0011" title="">Analysis 2.7</a>). </p> </li> </ol> </p> </section> <section id="CD001016-sec-0108"> <h6 class="title">2.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0109"> <h4 class="title">3. Progestogen therapy (luteal phase only) versus danazol</h4> <p>There were four trials comparing cyclical progestogen with danazol, all published before 1996. Three trials (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), used 200 mg danazol daily and one (<a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>), used decreasing dosages of danazol (200 mg, 100 mg and 50 mg per cycle) with a total of 107 women. </p> <section id="CD001016-sec-0110"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0111"> <h6 class="title">3.1 Menstrual blood loss</h6> <p>There was clear evidence of a difference in menstrual blood loss, measured by the alkaline haematin method, that favoured danazol compared with luteal phase norethisterone (MD 55.63, 95% CI 14.73 to 96.54; I<sup>2</sup> = 0%; 2 trials, 51 women; <a href="./references#CD001016-fig-0012" title="">Analysis 3.1</a> (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>)). </p> <p>There was clear evidence of a difference that favoured danazol in relation to the proportion of women with improvement in menstrual blood loss measured subjectively in two trials (Peto OR 0.24, 95% CI 0.08 to 0.69; I<sup>2</sup> = 0%; 2 trials, 54 women; <a href="./references#CD001016-fig-0013" title="">Analysis 3.2</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>)). </p> </section> <section id="CD001016-sec-0112"> <h6 class="title">3.2 Satisfaction</h6> <p>None of the trials reported data on the women's satisfaction with the treatment.</p> </section> </section> <section id="CD001016-sec-0113"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0114"> <h6 class="title">3.3 Days of bleeding</h6> <p>All four trials reported the number of days bleeding during the intervention menstrual cycle, reporting clear evidence of a difference that favoured danazol (MD 1.60, 95% CI 1.10 to 2.11; I<sup>2</sup> = 85%; 4 trials, 107 women; <a href="./references#CD001016-fig-0014" title="">Analysis 3.3</a>). </p> </section> <section id="CD001016-sec-0115"> <h6 class="title">3.4 Quality of life</h6> <p>None of the trials reported data on women's satisfaction or perceived change in quality.</p> </section> <section id="CD001016-sec-0116"> <h6 class="title">3.5 Compliance</h6> <p>Two trials (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>), reported no clear evidence of a difference in women's compliance with treatment between luteal phase norethisterone and danazol (Peto OR 1.56, 95% CI 0.45 to 5.45; I<sup>2</sup> = 0%; 2 trials, 61 women; <a href="./references#CD001016-fig-0015" title="">Analysis 3.4</a>). </p> </section> <section id="CD001016-sec-0117"> <h6 class="title">3.6 Acceptability</h6> <p>None of the trials reported data on the acceptability of the treatment for this comparison.</p> <p><b>3.7 Adverse events</b> </p> <p>Three trials (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>), reported adverse events, of any degree, reported either spontaneously by the woman or elicited from specific questioning. Two trials (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>), reported no clear evidence of difference in total adverse events between luteal phase norethisterone and danazol (Peto OR 0.34, 95% CI 0.13 to 0.88; I<sup>2</sup> = 0%; 2 trials, 77 women; <a href="./references#CD001016-fig-0016" title="">Analysis 3.5</a>). </p> <p>There was clear evidence that favoured luteal progestogen for:</p> <p> <ol id="CD001016-list-0020"> <li> <p>headache (Peto OR 0.29, 95% CI 0.09 to 0.95; I<sup>2</sup> = 0%; 2 trials, 64 women; <a href="./references#CD001016-fig-0017" title="">Analysis 3.6</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)); </p> </li> <li> <p>gastrointestinal symptoms (Peto OR 0.22, 95% CI 0.06 to 0.90; I<sup>2</sup> = 0%; 2 trials, 64 women; <a href="./references#CD001016-fig-0018" title="">Analysis 3.7</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)); </p> </li> <li> <p>weight gain (Peto OR 0.24, 95% CI 0.09 to 0.65; I<sup>2</sup> = 0%; 3 trials, 101 women; <a href="./references#CD001016-fig-0019" title="">Analysis 3.8</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>; <a href="./references#CD001016-bbs2-0008" title="HighamJM , ShawRW . A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. American Journal of Obstetrics and Gynecology1993;169:1134‐9. ">Higham 1993</a>)); </p> </li> <li> <p>skin changes (Peto OR 0.18, 95% CI 0.04 to 0.75; I<sup>2</sup> = 0%; 2 trials, 64 women; <a href="./references#CD001016-fig-0020" title="">Analysis 3.9</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>; <a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)). </p> </li> </ol> </p> <p>There was clear evidence that favoured danazol for:</p> <p> <ol id="CD001016-list-0021"> <li> <p>breast changes (Peto OR 8.73, 95% CI 1.14 to 67.13; 1 trial, 40 women; <a href="./references#CD001016-fig-0026" title="">Analysis 3.15</a> (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)). </p> </li> </ol> </p> <p>There was no clear evidence of difference in:</p> <p> <ol id="CD001016-list-0022"> <li> <p>neurological changes (Peto OR 1.00, 95% CI 0.20 to 4.90; 1 trial, 24 women; <a href="./references#CD001016-fig-0021" title="">Analysis 3.10</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>)); </p> </li> <li> <p>bloating (Peto OR 0.21, 95% CI 0.04 to 1.07; 1 trial, 24 women; <a href="./references#CD001016-fig-0022" title="">Analysis 3.11</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>)); </p> </li> <li> <p>voice change (Peto OR 6.00, 95% CI 0.34 to 106.33; 1 trial, 24 women; <a href="./references#CD001016-fig-0023" title="">Analysis 3.12</a> (<a href="./references#CD001016-bbs2-0002" title="BonduelleM , WalkerJJ , CalderAA . A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgraduate Medical Journal1991;67:833‐6. ">Bonduelle 1991</a>)); </p> </li> <li> <p>muscle cramps (Peto OR 1.40, 95% CI 0.28 to 7.02; 1 trial, 40 women; <a href="./references#CD001016-fig-0024" title="">Analysis 3.13</a> (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)); </p> </li> <li> <p>intermenstrual bleeding (Peto OR 0.26, 95% CI 0.04 to 1.67; 1 trial, 40 women; <a href="./references#CD001016-fig-0025" title="">Analysis 3.14</a> (<a href="./references#CD001016-bbs2-0003" title="BuyruF , YalcinO , KovanciE , TurfandaA . Danazol therapy in dysfunctional uterine bleeding. Istanbul Tip Fakultesi Mecmuasi1995;58(3):37‐40. ">Buyru 1995</a>)). </p> </li> </ol> </p> </section> <section id="CD001016-sec-0118"> <h6 class="title">3.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0119"> <h4 class="title">4. Progestogen therapy (luteal phase only) versus tranexamic acid</h4> <p>Three trials with a total of 216 women compared luteal norethisterone and tranexamic acid <b>(</b><a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>). </p> <section id="CD001016-sec-0120"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0121"> <h6 class="title">4.1 Menstrual blood loss</h6> <p>One trial (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>), showed clear evidence of a difference in menstrual blood loss measured by the alkaline haematin method favouring tranexamic acid when compared to luteal phase norethisterone (MD 111.00, 95% CI 43.54 to 178.46; 1 trial, 46 women; <a href="./references#CD001016-fig-0027" title="">Analysis 4.1</a>). </p> <p>One trial (<a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), showed no clear evidence of a difference between luteal phase norethisterone and tranexamic acid on the PBAC at three months (MD 25.00, 95% CI −15.54 to 65.54; 1 trial, 128 women; <a href="./references#CD001016-fig-0028" title="">Analysis 4.2</a>). </p> <p>Three trials (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>; <a href="./references#CD001016-bbs2-0015" title="ZhangY , HeF , LiS , CaoZ , LvS , LuJ . A multicenter, prospective, randomized open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in mainland China. Fertility and Sterility2007;88(1):s17‐18. [DOI: https://doi.org/10.1016/j.fertnstert.2007.07.076] ZhangY , HeF , SunZ , LiS , BiS , HuangX , et al. A multicenter, prospective, randomized, open comparator study on the treatment of ovulatory menorrhagia with tranexamic acid and norethisterone in China. Chinese Journal of Obstetrics and Gynaecology2008;43(4):247‐50. [CRSREF: 7929737] ">Zhang 2008</a>), showed clear evidence of a difference in the improvement of bleeding favouring tranexamic acid (Peto OR 0.43, 95% CI 0.25 to 0.75;; 3 trials, 216 women; I<sup>2</sup> = 9%; <a href="./references#CD001016-fig-0029" title="">Analysis 4.3</a>). </p> </section> <section id="CD001016-sec-0122"> <h6 class="title">4.2 Satisfaction</h6> <p>One trial (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), showed no clear evidence of a difference between luteal phase norethisterone and tranexamic acid for satisfaction with treatment (OR 1.33, 95% CI 0.37 to 4.85; 1 trial, 42 women; <a href="./references#CD001016-fig-0030" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD001016-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0124"> <h6 class="title">4.3 Days of bleeding</h6> <p>None of the trials reported data for the number of days of bleeding.</p> </section> <section id="CD001016-sec-0125"> <h6 class="title">4.4 Quality of life</h6> <p>There was no evidence of difference in the improvement in general health (Peto OR 0.45, 95% CI 0.14 to 1.47), dysmenorrhoea symptoms (Peto OR 0.44, 95% CI 0.12 to 1.59), ability to enjoy social activities (Peto OR 0.42, 95% CI 0.13 to 1.38) and improvement in sexual life (OR 0.29, 95% CI 0.07 to 1.29) between groups according to one trial with 44 women (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>). The same trial reported clear evidence of a difference favouring tranexamic acid for improvement of episodes of flooding and leakage (OR 0.16, 95% CI 0.04 to 0.66). See <a href="./references#CD001016-fig-0031" title="">Analysis 4.5</a>. </p> <p>One trial (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>) with 42 women showed no clear evidence of a difference between luteal phase norethisterone and tranexamic acid in quality of life measured with SF36 (<a href="./references#CD001016-fig-0032" title="">Analysis 4.6</a>) in the following areas: </p> <p> <ol id="CD001016-list-0023"> <li> <p>physical functioning (MD −0.73, 95% CI −2.25 to 0.79);</p> </li> <li> <p>social functioning (MD −0.37, 95% CI −2.46 to 1.72);</p> </li> <li> <p>mental health (MD −0.27, 95% CI −1.73 to 1.19);</p> </li> <li> <p>environmental domain (MD −1.20, 95% CI −2.57 to 0.17).</p> </li> </ol> </p> </section> <section id="CD001016-sec-0126"> <h6 class="title">4.5 Compliance</h6> <p>None of the trials reported data on compliance with treatment for this comparison.</p> </section> <section id="CD001016-sec-0127"> <h6 class="title">4.6 Acceptability</h6> <p>None of the trials reported data on the acceptability of the treatment for this comparison.</p> </section> <section id="CD001016-sec-0128"> <h6 class="title">4.7 Adverse events</h6> <p>There was no clear evidence of a difference between luteal phase norethisterone and tranexamic acid in adverse events: </p> <p> <ol id="CD001016-list-0024"> <li> <p>total adverse effects (Peto OR 0.93, 95% CI 0.33 to 2.64; I<sup>2</sup> = 15%; 2 trials, 88 women; <a href="./references#CD001016-fig-0033" title="">Analysis 4.7</a>) and gastrointestinal symptoms (Peto OR 1.69, 95% CI 0.54 to 5.34; I<sup>2</sup> = 67%; 2 trials, 88 women; <a href="./references#CD001016-fig-0035" title="">Analysis 4.9</a>) in two trials (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>; <a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>); </p> </li> <li> <p>headache (Peto OR 1.90, 95% CI 0.59 to 6.15; <a href="./references#CD001016-fig-0034" title="">Analysis 4.8</a>), weight gain (Peto OR 0.15, 95% CI 0.01 to 2.54; <a href="./references#CD001016-fig-0036" title="">Analysis 4.10</a>), dysmenorrhoea (Peto OR 1.48, 95% CI 0.32 to 6.71; <a href="./references#CD001016-fig-0038" title="">Analysis 4.12</a>) in one trial with 46 women (<a href="./references#CD001016-bbs2-0013" title="PrestonJT , CameronIT , AdamsEJ , SmithSK . Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. British Journal of Obstetrics &amp; Gynaecology1995;102:401‐6. ">Preston 1995</a>); </p> </li> <li> <p>bloating (Peto OR 8.61, 95% CI 0.52 to 142.87; <a href="./references#CD001016-fig-0037" title="">Analysis 4.11</a>) in one trial with 42 women (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>). </p> </li> </ol> </p> </section> <section id="CD001016-sec-0129"> <h6 class="title">4.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0130"> <h4 class="title">5. Progestogen therapy (luteal phase only) versus progestogen‐releasing intrauterine system </h4> <p>Two trials with a total of 49 women (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>; <a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), compared luteal phase norethisterone versus progestogen‐releasing intrauterine devices: one trial (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), used a device releasing 65 μg progesterone daily (Pg‐IUS), and the other trial (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), used an intrauterine system releasing 20 μg of levonorgestrel daily (LNG‐IUS). </p> <section id="CD001016-sec-0131"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0132"> <h6 class="title">5.1 Menstrual blood loss</h6> <p>One trial (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), showed clear evidence of a difference in menstrual blood loss between luteal phase norethisterone and Pg‐IUS, favouring the Pg‐IUS, using the alkaline haematin method (MD 51.00, 95% CI 18.38 to 83.62; 1 trial, 16 women; <a href="./references#CD001016-fig-0039" title="">Analysis 5.1</a>). </p> <p>One trial (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), showed clear evidence of an improvement in menstrual blood loss between luteal phase norethisterone and LNG‐IUS, favouring the LNG‐IUS, assessed by the proportion of women with a PBAC less than 100 at six‐month follow‐up (Peto OR 0.11, 95% CI 0.03 to 0.38; 1 trial, 40 women; <a href="./references#CD001016-fig-0040" title="">Analysis 5.2</a>). </p> </section> <section id="CD001016-sec-0133"> <h6 class="title">5.2 Satisfaction</h6> <p>One trial (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), showed no clear evidence of difference between treatments on the satisfaction rate (Peto OR 0.43, 95% CI 0.10 to 1.87; 1 trial, 40 women; <a href="./references#CD001016-fig-0041" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD001016-sec-0134"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0135"> <h6 class="title">5.3 Days of bleeding</h6> <p>One trial (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), showed no clear evidence of difference between treatments in the number of days of bleeding (MD 1.00, 95% CI −0.19 to 2.19; 1 trial, 16 women; <a href="./references#CD001016-fig-0042" title="">Analysis 5.4</a>). </p> </section> <section id="CD001016-sec-0136"> <h6 class="title">5.4 Quality of life</h6> <p>One trial with 40 women (<a href="./references#CD001016-bbs2-0011" title="KiseliM , KayikciogluF , EvliyaogluO , HaberalA . Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel‐releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecologic and Obstetric Investigation2016;81(5):447‐53. [CRSSTD: 7929734] ">Kiseli 2016</a>), showed no clear evidence of a difference between treatments on quality of life in the following areas (<a href="./references#CD001016-fig-0043" title="">Analysis 5.5</a>): </p> <p> <ol id="CD001016-list-0025"> <li> <p>physical domain (MD 0.03, 95% CI −6.21 to 6.27);</p> </li> <li> <p>psychological domain (MD −0.67, 95% CI −7.49 to 6.15);</p> </li> <li> <p>social domain (MD −0.14, 95% CI −9.33 to 9.05);</p> </li> <li> <p>environmental domain (MD −0.20, 95% CI −6.34 to 5.94).</p> </li> </ol> </p> </section> <section id="CD001016-sec-0137"> <h6 class="title">5.5 Compliance</h6> <p>Neither of the included trials reported data on compliance with treatment for this comparison. </p> </section> <section id="CD001016-sec-0138"> <h6 class="title">5.6 Acceptability</h6> <p>Neither of the included trials reported data on the acceptability of the treatment for this comparison. </p> </section> <section id="CD001016-sec-0139"> <h6 class="title">5.7 Adverse events</h6> <p>Neither of the included trials reported data on side effects for this comparison.</p> </section> <section id="CD001016-sec-0140"> <h6 class="title">5.8 Resource use and cost</h6> <p>Neither of the included trials reported data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0141"> <h4 class="title">6. Progestogen therapy (medroxyprogesterone acetate, (luteal phase only) versus progestogen‐releasing intrauterine system </h4> <p>One trial, with 162 women in three countries (<a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a>), compared 10 mg a day of medroxyprogesterone acetate from day 16 to 25 of the cycle versus LNG‐IUS. </p> <section id="CD001016-sec-0142"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0143"> <h6 class="title">6.1 Menstrual blood loss</h6> <p>There was clear evidence of a difference in menstrual blood loss, measured by a reduction of PBAC from baseline, favouring the LNG‐IUS (MD −49.30, 95% CI −69.91 to −28.69; 1 trial, 165 women; <a href="./references#CD001016-fig-0044" title="">Analysis 6.1</a>). </p> </section> <section id="CD001016-sec-0144"> <h6 class="title">6.2 Satisfaction</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on satisfaction with treatment. </p> </section> </section> <section id="CD001016-sec-0145"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0146"> <h6 class="title">6.3 Days of bleeding</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on days of bleeding for this comparison. </p> </section> <section id="CD001016-sec-0147"> <h6 class="title">6.4 Quality of life</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on quality of life for this comparison. </p> </section> <section id="CD001016-sec-0148"> <h6 class="title">6.5 Compliance</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on compliance with treatment for this comparison. </p> </section> <section id="CD001016-sec-0149"> <h6 class="title">6.6 Acceptability</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on the acceptability of the treatment for this comparison. </p> <p><b>6.7 Adverse events</b> </p> <p>There was clear evidence of a difference in the adverse effect 'ovarian cyst', favouring luteal progestogen (OR 0.17, 95% CI 0.04 to 0.83; <a href="./references#CD001016-fig-0045" title="">Analysis 6.2</a>). All the ovarian cysts in the trial were characterized as mild events that were thought to be related to treatment with trial medication. </p> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> showed no clear evidence of a difference in 162 women for the following adverse effects (<a href="./references#CD001016-fig-0045" title="">Analysis 6.2</a>). </p> <p> <ol id="CD001016-list-0026"> <li> <p>Pelvic pain (Peto OR 0.49, 95% CI 0.10 to 2.49)</p> </li> <li> <p>Headache (Peto OR 1.56, 95% CI 0.64 to 3.83)</p> </li> <li> <p>Breast tenderness (Peto OR 0.72, 95% CI 0.16 to 3.28)</p> </li> <li> <p>Vaginitis (Peto OR 3.00, 95% CI 0.93 to 9.70)</p> </li> <li> <p>Acne (Peto OR 1.03, 95% CI 0.29 to 3.68)</p> </li> <li> <p>Hypertension (Peto OR 4.06, 95% CI 0.80 to 20.65)</p> </li> <li> <p>Sinusitis (Peto OR 1.73, 95% CI 0.42 to 7.14)</p> </li> <li> <p>Fatigue (Peto OR 2.04, 95% CI 0.40 to 10.38)</p> </li> <li> <p>Urinary tract infection (Peto OR 2.07, 95% CI 0.54 to 7.91)</p> </li> <li> <p>Increased weight (Peto OR 0.81, 95% CI 0.21 to 3.10)</p> </li> </ol> </p> </section> <section id="CD001016-sec-0150"> <h6 class="title">6.8 Resource use and cost</h6> <p><a href="./references#CD001016-bbs2-0010" title="KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , DeSanctisY , Jensen . Levonorgestrel‐releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception2012;86(5):452‐7. [CRSREF: 3289391] KaunitzAM , BissonnetteF , MonteiroI , Lukkari‐LaxE , MuysersC , JensenJT . Levonorgestrel‐releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding. Obstetrics and Gynecology2010;116:3625‐32. [CRSREF: 328939] ">Kaunitz 2010</a> did not report data on resource use or costs for this comparison. </p> </section> </section> </section> <section id="CD001016-sec-0151"> <h4 class="title">7. Progestogen therapy (3 to 4 weeks) versus progestogen‐releasing intrauterine system (LNG‐IUS) </h4> <p>Two trials, with 120 women in total (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>; <a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>), compared norethisterone from day 5 to 26 of the cycle and the LNG‐IUS. </p> <section id="CD001016-sec-0152"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0153"> <h6 class="title">7.1 Menstrual blood loss</h6> <p>One trial (<a href="./references#CD001016-bbs2-0009" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1988;105(6):592‐8. ">Irvine 1998</a>), showed clear evidence of a difference between groups for menstrual blood loss favouring the LNG‐IUS, as measured by alkaline haematin; although there was a substantial reduction from baseline in both groups. We have not included these results in the graphical display because the data were not normally distributed (see <a href="./references#CD001016-fig-0046" title="">Analysis 7.1</a>). </p> <p>There was clear evidence of a difference in the proportion of women with menstrual blood loss lower than 80 mL after treatment favouring the LNG‐IUS (Peto OR 0.23, 95% CI 0.09 to 0.57; I<sup>2</sup> = 0%; 2 trials, 120 women; <a href="./references#CD001016-fig-0047" title="">Analysis 7.2</a>). </p> <p>One trial, with 76 women (<a href="./references#CD001016-bbs2-0001" title="AshrafMN , Habib‐Ur‐RehmanA , ShehzadZ , AlSharariSD , MurtazaG . Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. Journal of Pakistan Medical Association2017;67(9):1331‐8. [PMID: 28924270] ">Ashraf 2017</a>), did not report a clear difference in menstrual blood loss at three months' follow‐up using the PBAC (MD 29.00, 95% CI −609.14 to 667.14; <a href="./references#CD001016-fig-0048" title="">Analysis 7.3</a>); but the same trial reported clear evidence of a difference favouring the LNG‐IUS at six months (MD 21.42, 95% CI 14.24 to 28.60; <a href="./references#CD001016-fig-0049" title="">Analysis 7.4</a>). </p> </section> <section id="CD001016-sec-0154"> <h6 class="title">7.2 Satisfaction</h6> <p>Neither of the included trials reported women's satisfaction with the treatment for this comparison. </p> </section> </section> <section id="CD001016-sec-0155"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0156"> <h6 class="title">7.3 Days of bleeding</h6> <p>Neither of the included trials reported days of bleeding for this comparison.</p> <p><b>7.4 Quality of life</b> </p> <p>There was no evidence of a clear difference in improvement in quality of life between groups for dysmenorrhoea (Peto OR 2.12, 95% CI 0.42 to 10.79; 1 trial, 31 women; <a href="./references#CD001016-fig-0050" title="">Analysis 7.5</a>). </p> </section> <section id="CD001016-sec-0157"> <h6 class="title">7.5 Compliance</h6> <p>Neither of the included trials reported compliance with treatment for this comparison.</p> </section> <section id="CD001016-sec-0158"> <h6 class="title">7.6 Acceptability</h6> <p>There was clear evidence of a difference in treatment acceptability of the treatment favouring the LNG‐IUS (Peto OR 0.12, 95% CI 0.03 to 0.40: 1 trial, 40 women; <a href="./references#CD001016-fig-0051" title="">Analysis 7.6</a>). </p> </section> <section id="CD001016-sec-0159"> <h6 class="title">7.7 Adverse events</h6> <p>There was clear evidence of differences in the following side effects favouring the oral progestogens: </p> <p> <ol id="CD001016-list-0027"> <li> <p>intermenstrual bleeding (Peto OR 0.23, 95% CI 0.05 to 0.99; 1 trial, 31 women; <a href="./references#CD001016-fig-0052" title="">Analysis 7.7</a>); </p> </li> <li> <p>breast tenderness (Peto OR 0.11, 95% CI 0.03 to 0.46; 1 trial, 31 women; <a href="./references#CD001016-fig-0053" title="">Analysis 7.8</a>). </p> </li> </ol> </p> <p>There was no clear evidence of a difference between groups for mood swings (Peto OR 0.82, 95% CI 0.19 to 3.54; 1 trial, 31 women; <a href="./references#CD001016-fig-0054" title="">Analysis 7.9</a>). </p> </section> <section id="CD001016-sec-0160"> <h6 class="title">7.8 Resource use and cost</h6> <p>Neither of the included trials reported data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0161"> <h4 class="title">8. Progestogen therapy (3 to 4 weeks) versus tranexamic acid</h4> <p>Two trials, with 184 women in total (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>; <a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>), compared medroxyprogesterone acetate for 21 days per cycle (from day 5 to 26) with tranexamic acid. </p> <section id="CD001016-sec-0162"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0163"> <h6 class="title">8.1 Menstrual blood loss</h6> <p>There was no clear evidence of a difference between groups in the PBAC at three months (MD 8.82, 95% CI −12.09 to 29.73; I<sup>2</sup> = 0%; 2 trials, 184 women; <a href="./references#CD001016-fig-0055" title="">Analysis 8.1</a>). </p> <p>One trial (<a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>), showed clear evidence of an improvement in bleeding rates favouring tranexamic acid (Peto OR 0.20, 95% CI 0.07 to 0.59; 1 trial, 94 women; <a href="./references#CD001016-fig-0056" title="">Analysis 8.2</a>). </p> </section> <section id="CD001016-sec-0164"> <h6 class="title">8.2 Satisfaction</h6> <p>The included trials did not report satisfaction with treatment.</p> </section> </section> <section id="CD001016-sec-0165"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0166"> <h6 class="title">8.3 Days of bleeding</h6> <p>The included trials did not report days of bleeding.</p> </section> <section id="CD001016-sec-0167"> <h6 class="title">8.4 Quality of life</h6> <p>One trial with 90 women (<a href="./references#CD001016-bbs2-0006" title="GoshtasebiA , MoukhahS , GandevaniSB . Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Archives of Gynecology and Obstetrics2013;288(5):1055‐60. [CRSREF: 3225319] ">Goshtasebi 2013</a>), reported no clear evidence of a difference in quality of life between treatments using the SF36 for the following aspects (<a href="./references#CD001016-fig-0057" title="">Analysis 8.3</a>). </p> <p> <ol id="CD001016-list-0028"> <li> <p>Physical functioning (MD −1.50, 95% CI −6.77 to 3.77)</p> </li> <li> <p>Role physical (MD −4.00, 95% CI −13.63 to 5.63)</p> </li> <li> <p>Bodily pain (MD 2.80, 95% CI −6.01 to 11.61)</p> </li> <li> <p>General health (MD −5.00, 95% CI −12.49 to 2.49)</p> </li> <li> <p>Vitality (MD −1.40, 95% CI −9.42 to 6.62)</p> </li> <li> <p>Social functioning (MD 1.10, 95% CI −5.36 to 7.56)</p> </li> <li> <p>Role emotional (MD 0.50, 95% CI −11.47 to 12.47)</p> </li> <li> <p>Mental health (MD 2.90, 95% CI −4.83 to 10.63)</p> </li> </ol> </p> </section> <section id="CD001016-sec-0168"> <h6 class="title">8.5 Compliance</h6> <p>The included trials did not report compliance with treatment for this comparison.</p> </section> <section id="CD001016-sec-0169"> <h6 class="title">8.6 Acceptability</h6> <p>The included trials did not report the acceptability of the treatment for this comparison.</p> </section> <section id="CD001016-sec-0170"> <h6 class="title">8.7 Adverse events</h6> <p>One trial, with 94 women (<a href="./references#CD001016-bbs2-0012" title="KriplaniA , KulshresthaV , AgarwalN , DiwakarS . Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. Journal of Obstetrics and Gynaecology2006;26(7):673‐8. [CRSREF: 3225323] ">Kriplani 2006</a>), showed no clear evidence of a difference between treatments for any of the following adverse effects (<a href="./references#CD001016-fig-0058" title="">Analysis 8.4</a>). </p> <p> <ol id="CD001016-list-0029"> <li> <p>Any adverse effects (Peto OR 0.40, 95% CI 0.16 to 1.03)</p> </li> <li> <p>Gastrointestinal event (Peto OR 1.39, 95% CI 0.23 to 8.36)</p> </li> <li> <p>Headache (Peto OR 1.39, 95% CI 0.23 to 8.36)</p> </li> <li> <p>Allergic reaction (Peto OR 6.81, 95% CI 0.13 to 344.42)</p> </li> <li> <p>Intermenstrual bleeding (Peto OR 0.11, 95% CI 0.02 to 0.68)</p> </li> <li> <p>Giddiness (Peto OR 0.33, 95% CI 0.04 to 2.39)</p> </li> <li> <p>Breast tenderness (Peto OR 0.12, 95% CI 0.01 to 1.97)</p> </li> <li> <p>Mood changes (Peto OR 0.12, 95% CI 0.00 to 6.26)</p> </li> </ol> </p> </section> <section id="CD001016-sec-0171"> <h6 class="title">8.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0172"> <h4 class="title">9. Progestogen therapy (3 to 4 weeks) versus ormeloxifene</h4> <p>One trial, with 72 women <b>(</b><a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a>), compared medroxyprogesterone acetate and ormeloxifene. <a href="./references#CD001016-bbs2-0014" title="ShravageJ , MekhalaD , BelladMB , GanachariMS , DhumaleHA . Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding. A double blind randomized controlled trial. Journal of South Asian Federation of Obstetrics and Gynaecology2011;3(1):21‐4. [10.5005/jp‐journals‐10006‐1116] ">Shravage 2011</a> presented data in a format that did not allow us to combine them. We contacted the trial authors for clarification. </p> <p>At the end of the first month, no statistically significant difference was reported in terms of PBAC. At the end of the third month, there was clear evidence of a higher reduction in PBAC score favouring ormeloxifene (P = 0.014). </p> <p> <div class="table" id="CD001016-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Mean PBAC after 3 months' treatment</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean PBAC</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ormeloxifene</b> </p> <p><b>twice a week</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medroxyprogesterone</b> </p> <p><b>acetate 21 d</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100‐185</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 185</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42</b> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD001016-sec-0173"> <h4 class="title">10. Progestogen therapy (3 to 4 weeks) versus combined vaginal ring</h4> <p>One trial, with 95 women (<a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a>), compared norethisterone for 21 days (day 5 to 26 of the cycle) and the combined vaginal ring. The combined vaginal ring is a polymeric drug delivery device designed to provide controlled release of drugs for intravaginal administration over extended periods of time. The combined vaginal ring releases 15 ug of ethinyl oestradiol and 120 ug of etonogestrel daily over a single cycle, the ring was inserted between days 1 and 5 of the menstrual cycle for 3 weeks, followed by a 1‐week, ring‐free period. </p> <section id="CD001016-sec-0174"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0175"> <h6 class="title">10.1 Menstrual blood loss</h6> <p>There was no clear evidence of difference between treatments in menstrual blood loss at the end of the trial (MD 2.10, 95% CI −8.15 to 12.35; <a href="./references#CD001016-fig-0059" title="">Analysis 10.1</a>) or in the percentage change or reduction in menstrual blood loss (<a href="./references#CD001016-fig-0060" title="">Analysis 10.2</a>). </p> </section> <section id="CD001016-sec-0176"> <h6 class="title">10.2 Satisfaction</h6> <p>There was clear evidence of a difference in satisfaction with treatment, favouring the combined vaginal ring (Peto OR 0.32, 95% CI 0.14 to 0.72; <a href="./references#CD001016-fig-0061" title="">Analysis 10.3</a>). </p> </section> </section> <section id="CD001016-sec-0177"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0178"> <h6 class="title">10.3 Days of bleeding</h6> <p><a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a> did not report any data on days of bleeding for this comparison. </p> </section> <section id="CD001016-sec-0179"> <h6 class="title">10.4 Quality of life</h6> <p>There was no clear evidence of a difference between treatments for:</p> <p> <ol id="CD001016-list-0030"> <li> <p>HRQoL‐ 4 self‐rated health (Peto OR 0.78, 95% CI 0.33 to 1.82; <a href="./references#CD001016-fig-0062" title="">Analysis 10.4</a>); </p> </li> <li> <p>HRQoL‐4 impairment or lost days in terms of feeling physically unwell (MD 0.20, 95% CI −0.28 to 0.68) or mentally unwell (MD 0.40, 95% CI −0.10 to 0.90; <a href="./references#CD001016-fig-0063" title="">Analysis 10.5</a>). </p> </li> </ol> </p> <p>There was clear evidence of a difference favouring the combined vaginal ring in the number of lost days (days with no regular activities) (MD 0.90, 95% CI 0.38 to 1.42; <a href="./references#CD001016-fig-0063" title="">Analysis 10.5</a>). </p> </section> <section id="CD001016-sec-0180"> <h6 class="title">10.5 Compliance</h6> <p><a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a> did not report any data on compliance with treatment for this comparison. </p> </section> <section id="CD001016-sec-0181"> <h6 class="title">10.6 Acceptability</h6> <p><a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a> did not report any data on the acceptability of the treatment for this comparison. </p> </section> <section id="CD001016-sec-0182"> <h6 class="title">10.7 Adverse events</h6> <p>There was no clear evidence of a difference for the following adverse effects (<a href="./references#CD001016-fig-0064" title="">Analysis 10.6</a>). </p> <p> <ol id="CD001016-list-0031"> <li> <p>Nausea (Peto OR 2.02, 95% CI 0.20 to 19.90)</p> </li> <li> <p>Headache (Peto OR 0.67, 95% CI 0.11 to 4.04)</p> </li> <li> <p>Breast tenderness (Peto OR 1.55, 95% CI 0.26 to 9.31)</p> </li> <li> <p>Breakthrough bleeding or spotting (Peto OR 3.01, 95% CI 0.71 to 12.73)</p> </li> <li> <p>Vaginal discharge (leukorrhoea) (Peto OR 0.24, 95% CI 0.05 to 1.27)</p> </li> <li> <p>Vaginal discomfort (Peto OR 0.14, 95% CI 0.01 to 2.20)</p> </li> <li> <p>Vaginitis (Peto OR 0.29, 95% CI 0.05 to 1.75)</p> </li> </ol> </p> </section> <section id="CD001016-sec-0183"> <h6 class="title">10.8 Resource use and cost</h6> <p><a href="./references#CD001016-bbs2-0007" title="Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception2012;85(3):246‐52. [10.1016/j.contraception.2011.07.012] Abu HashimH , AlsherbiniW , BazeedM . Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Obstetrical &amp; Gynecological Survey2012;67(11):696‐7. [DOI: 10.1097/01.ogx.0000423185.87629.6e] ">Hashim 2012</a> did not report data on resource use or costs for this comparison. </p> </section> </section> </section> <section id="CD001016-sec-0184"> <h4 class="title">11. Overall analysis 1: progestogen therapy (luteal phase only) versus any other medical therapy (all types combined) </h4> <section id="CD001016-sec-0185"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0186"> <h6 class="title">11.1 Menstrual blood loss</h6> <p>There was clear evidence of a difference between luteal progestogen and other medical therapy, favouring other medical therapy. Measuring blood loss using the alkaline haematin method, the progestogen group blood loss was on average 37 mL higher than on the other medical treatments (MD 37.29, 95% CI 17.67 to 56.91; I<sup>2</sup> = 50%; 4 trials, 145 women; low‐quality evidence; <a href="./references#CD001016-fig-0065" title="">Analysis 11.1</a>). </p> </section> <section id="CD001016-sec-0187"> <h6 class="title">11.2 Satisfaction</h6> <p>There was no clear evidence of a difference between treatments in terms of satisfaction (OR 0.80, 95% CI 0.17 to 3.80; I<sup>2</sup> = 0%; 1 trial, 52 women; very low‐quality evidence; <a href="./references#CD001016-fig-0066" title="">Analysis 11.2</a>). </p> </section> </section> <section id="CD001016-sec-0188"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0189"> <h6 class="title">11.3 Days of bleeding</h6> <p>There was clear evidence of a difference in the number of days of bleeding between treatments favouring other medical treatments (MD 1.05, 95% CI 0.69 to 1.40; I<sup>2</sup> = 81%; 5 trials, 171 women; very low‐quality evidence; <a href="./references#CD001016-fig-0067" title="">Analysis 11.3</a>). The high heterogeneity is probably because of the nature of the outcome. It is inherently unreliable as it is subjective and self‐reported, a day has 24 hours and it is not specific to the days of menstrual bleeding (so it could include days of intermenstrual bleeding too). </p> </section> <section id="CD001016-sec-0190"> <h6 class="title">11.4 Quality of life</h6> <p>There was no clear evidence of a difference between treatments in terms of physical well‐being (MD −0.43, 95% CI −5.10 to 4.24; I<sup>2</sup> = 0%; 1 trial, 62 women; very low‐quality evidence; <a href="./references#CD001016-fig-0068" title="">Analysis 11.4</a>). </p> </section> <section id="CD001016-sec-0191"> <h6 class="title">11.5 Compliance</h6> <p>The included trials did not report any data on compliance with treatment for this comparison. </p> </section> <section id="CD001016-sec-0192"> <h6 class="title">11.6 Acceptability</h6> <p>The included trials did not report any data on the acceptability of the treatment for this comparison. </p> </section> <section id="CD001016-sec-0193"> <h6 class="title">11.7 Adverse events</h6> <p>There was no clear evidence of a difference between treatments on total adverse effects (OR 0.68, 95% CI 0.36 to 1.28; I<sup>2</sup> = 31%; 5 trials, 197 women; very low‐quality evidence; <a href="./references#CD001016-fig-0069" title="">Analysis 11.5</a>). </p> </section> <section id="CD001016-sec-0194"> <h6 class="title">11.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> <section id="CD001016-sec-0195"> <h4 class="title">12. Overall analysis 2: progestogen therapy long cycle (3 to 4 weeks) versus any other medical therapy (all types combined) </h4> <section id="CD001016-sec-0196"> <h5 class="title">Primary outcomes</h5> <section id="CD001016-sec-0197"> <h6 class="title">12.1 Menstrual blood loss</h6> <p>There was clear evidence of a difference in the PBAC:</p> <p> <ol id="CD001016-list-0032"> <li> <p>at three months' follow‐up between groups, favouring other medical therapy (MD 16.88, 95% CI 10.93 to 22.84; I<sup>2</sup> = 87%; 4 trials, 355 women; very low‐quality evidence; <a href="./references#CD001016-fig-0070" title="">Analysis 12.1</a>). Heterogeneity is high because the comparison is versus other medical treatments in general and the other medical treatments vary considerably. </p> </li> <li> <p>at six months' follow‐up between groups, favouring other medical therapy (MD 21.42, 95% CI 14.24 to 28.60; 1 trial, 76 women; low‐quality evidence; <a href="./references#CD001016-fig-0071" title="">Analysis 12.2</a>). </p> </li> </ol> </p> </section> <section id="CD001016-sec-0198"> <h6 class="title">12.2 Satisfaction</h6> <p>There was evidence of a difference in terms of satisfaction favouring other medical therapies (OR 0.31, 95% CI 0.13 to 0.71; 1 trial, 95 women; low‐quality evidence; <a href="./references#CD001016-fig-0072" title="">Analysis 12.3</a>). </p> </section> </section> <section id="CD001016-sec-0199"> <h5 class="title">Secondary outcomes</h5> <section id="CD001016-sec-0200"> <h6 class="title">12.3 Days of bleeding</h6> <p>None of the included trials reported data on the number of days of bleeding for this comparison. </p> </section> <section id="CD001016-sec-0201"> <h6 class="title">12.4 Quality of life</h6> <p>The included trials did not report data on quality of life for this comparison.</p> </section> <section id="CD001016-sec-0202"> <h6 class="title">12.5 Compliance</h6> <p>The included trials did not report data on compliance with treatment for this comparison.</p> </section> <section id="CD001016-sec-0203"> <h6 class="title">12.6 Acceptability</h6> <p>There was clear evidence of difference on acceptability of treatment favours other medical treatment, specifically LNG IUS, compared to long cycle oral progesterone (OR 0.08, 95% CI 0.02 to 0.37; 40 women; one study; <a href="./references#CD001016-fig-0073" title="">Analysis 12.4</a>). </p> <p><b>12.7 Adverse events</b> </p> <p> <ol id="CD001016-list-0033"> <li> <p>There was no clear evidence of a difference between progestogen therapy long cycle and other medical therapy in terms of headache (OR 1.45, 95% CI 0.40 to 5.31; I<sup>2</sup> = 0%; 2 trials, 189 women; low‐quality evidence; <a href="./references#CD001016-fig-0074" title="">Analysis 12.5</a>). </p> </li> <li> <p>There was clear evidence of a difference between groups in terms of breakthrough bleeding or spotting favouring the progestogen long cycle (OR 0.18, 95% CI 0.06 to 0.55; I<sup>2</sup> = 0%; 3 trials, 220 women; low‐quality evidence; <a href="./references#CD001016-fig-0075" title="">Analysis 12.6</a>). </p> </li> </ol> </p> </section> <section id="CD001016-sec-0204"> <h6 class="title">12.8 Resource use and cost</h6> <p>The included trials did not report data on resource use or costs for this comparison.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001016-sec-0205" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001016-sec-0205"></div> <section id="CD001016-sec-0206"> <h3 class="title" id="CD001016-sec-0206">Summary of main results</h3> <p>Based on the available evidence, this review was not able to meet all of its objectives in determining the effectiveness of oral progestogens in the treatment of HMB. We did not identify any RCTs comparing oral progestogens with placebo, and none of the trials under consideration assessed resource use or cost effectiveness. </p> <section id="CD001016-sec-0207"> <h4 class="title">Primary outcomes</h4> <section id="CD001016-sec-0208"> <h5 class="title">Progestogen therapy (luteal phase only) compared to other medical treatment</h5> <p>See <a href="./full#CD001016-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Luteal phase progestogens were less effective at reducing menstrual blood loss (as measured by the alkaline haematin method and the number of days bleeding during menstruation) when compared to other medical treatments such as tranexamic acid, danazol and the progestogen‐releasing intrauterine system. We are uncertain whether luteal phase progestogen improves satisfaction or quality of life of women with HMB, or is associated with any difference in adverse effects when compared to other medical treatments. Even though luteal phase progestogen was less effective at reducing menstrual blood loss, satisfaction with treatment was similar to other medical treatments such as tranexamic acid and Pg‐IUS. </p> </section> <section id="CD001016-sec-0209"> <h5 class="title">Progestogen therapy long cycle (three to four weeks) compared to other medical therapy</h5> <p>See <a href="./full#CD001016-tbl-0002">summary of findings Table 2</a>. </p> <p>Long‐cycle oral progestogens (3 to 4 weeks, either norethisterone or medroxyprogesterone acetate) produced a reduction in menstrual blood loss from baseline measurements, but appeared to be less effective than the LNG‐IUS in reducing menstrual loss at three and six months' follow‐up. There was no difference in the occurrence of headache, but long‐cycle oral progestogens were associated with a significantly lower incidence of breakthrough bleeding compared with other medical treatment. Satisfaction with treatment was similar to women using the combined vaginal ring, but there were no data to compare satisfaction between long cycle and LNG‐IUS or tranexamic acid. </p> <p>This review does not support the hypothesis that treatment with oral progestogen is more effective than other medical therapies in reducing menstrual blood loss. Luteal phase progestogens were less effective at reducing menstrual blood loss when compared to tranexamic acid, danazol and the Pg‐IUS, and there was no clear evidence of a difference when compared with NSAIDs. Long‐cycle oral progestogens (3 to 4 weeks) produced a significant reduction in menstrual blood loss, but appeared to be less effective than the LNG‐IUS. </p> </section> </section> <section id="CD001016-sec-0210"> <h4 class="title">Other outcomes</h4> <p>Oral progestogens in the luteal phase were associated with a lower incidence of adverse events than danazol, but no difference was observed when oral progestogens were compared with mefenamic acid or tranexamic acid. Women treated with the longer course of norethisterone, from day 5 to day 26 of the cycle, had a lower incidence of intermenstrual bleeding and breast tenderness than those treated with the LNG‐IUS. Without placebo trials, it is difficult to put these findings into context, since both danazol and the LNG‐IUS are known to be associated with a significant number of adverse effects. A high incidence of adverse effects can result in poor patient compliance, but we noted no difference in patient compliance when comparing luteal phase progestogen with mefenamic acid or danazol; the LNG‐IUS was associated with a higher patient acceptability than the longer regimen of norethisterone. </p> <p>Only six of the 15 trials assessed quality of life. They demonstrated no significant difference in improved general health, symptoms of dysmenorrhoea or an ability to enjoy life, between progestogen‐ and tranexamic acid‐treated women, although a greater proportion of these women had improvement in their sex life, and flooding and leakage problems with tranexamic acid. </p> </section> </section> <section id="CD001016-sec-0211"> <h3 class="title" id="CD001016-sec-0211">Overall completeness and applicability of evidence</h3> <p>This Cochrane Review included 15 trials with data that were relevant to this review question. </p> <p>The review illustrates the importance of conducting objective RCTs of medical therapy for the treatment of HMB. The first subjective trial using progestogens for the treatment of HMB was published in 1960 (<a href="./references#CD001016-bbs2-0021" title="BishopPM , deAlmeidaJC . Treatment of functional menstrual disorders with norethisterone. British Medical Journal1960;1:1103‐5. ">Bishop 1960</a>). It was not until 27 years later that a randomized trial using objective measurements of menstrual blood loss was carried out (<a href="./references#CD001016-bbs2-0004" title="CameronIT , LeaskR , KellyRW , BairdDT . The effects of danazol, mefenamic acid, norethisterone and a progesterone‐impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins1987;34:99‐110. ">Cameron 1987</a>), demonstrating no significant reduction in menstrual blood loss with norethisterone 5 mg twice daily from day 15 to 25 of the cycle (short cycle). Additional RCTs have investigated the effectiveness of a longer cycle of progestogens (from days 5 to 26 of the menstrual cycle) but have found no evidence that this treatment is better than other medical treatments, such as LNG‐IUS and tranexamic acid. Despite this, and the other papers included in this review, oral progestins remain commonly prescribed for the treatment of HMB. According to a 2009 national survey in the USA, oral progestogen is one of the first three options for treating HMB for up for up to 60% of gynaecologists (<a href="./references#CD001016-bbs2-0038" title="MattesonK , AndresonB , PintoS , LopesV , SchulkinJ , ClarkM . Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. American Journal of Obstetrics and Gynaecology2011;205(4):321.e1–321.e8. [DOI: 10.1016/j.ajog.2011.05.016.] ">Matteson 2011</a>), In South Korea, oral progestogen is the second most common choice for HMB, and the first option for 13% of gynaecologists (<a href="./references#CD001016-bbs2-0036" title="LeeJY , LeeDY , SongJY , LeeES , JeongK , ChoiD . A national survey of gynecologists on current practice patterns for management of abnormal uterine bleeding in South Korea. International Journal of Gynaecology and Obstetrics2015;131(1):74‐7. [DOI: 10.1016/j.ijgo.2015.04.034] ">Lee 2015</a>). </p> </section> <section id="CD001016-sec-0212"> <h3 class="title" id="CD001016-sec-0212">Quality of the evidence</h3> <p>The methodological quality of the evidence varied from low to very low. The main limitations were risk of bias (associated with high risk of detection and attrition bias) and inconsistency (due to high heterogeneity). </p> <p>For the primary outcome of menstrual bleeding, different trials used different ways to assess the bleeding and to determine if there was any improvement. This is a major limitation when attempting to pool data. </p> <p>For some comparisons, only one trial reported data, which contributes to the lack of power. </p> </section> <section id="CD001016-sec-0213"> <h3 class="title" id="CD001016-sec-0213">Potential biases in the review process</h3> <p>We attempted to identify and include all relevant work through the standardized method of identifying trials, but it is always possible that we may have missed some trials. Not all trial authors responded to our requests for more information, so we used imputation for some data. Some trial authors responded to the communications but did not submit the data requested. </p> <p>We attempted to minimize potential biases in the review process by undertaking duplicate selection of trials, data extraction, and assessment of risk of bias. If there was disagreement, we resolved this through discussion and reaching consensus, but no intervention of a third review author was needed. </p> </section> <section id="CD001016-sec-0214"> <h3 class="title" id="CD001016-sec-0214">Agreements and disagreements with other studies or reviews</h3> <p>The results of this review are in accordance with other reviews.</p> <p>The ECLIPSE trial (<a href="./references#CD001016-bbs2-0017" title="GuptaJ , KaiJ , MiddletonL , PattisonH , GrayR , DanielsJ . Levonorgestrel intrauterine system versus medical therapy for menorrhagia. New England Journal of Medicine2013;368:128‐37. [CRSREF: 3289371] ">Gupta 2013</a>), randomly assigned 571 women with HMB to the LNG‐IUS or to other usual medical treatment, including oral cyclical progesterone. Both groups improved from baseline and the improvement was maintained over two years, but was significantly better in the LNG‐IUS group. </p> <p>According to a recent comprehensive review of the literature (<a href="./references#CD001016-bbs2-0022" title="BitzerJ , HeikinheimoO , NelsonA , Calaf‐AlsinaJ , FraserI . Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstetrics and Gynecolgy Survey2015;70(2):115‐30. [10.1097/ogx.0000000000000155] ">Bitzer 2015</a>), the data available assessing the use of luteal phase progestogen were inconsistent or suggested a very limited efficacy in reducing HMB, with an eventual increase after treatment. Long‐cycle progestogens (3 to 4 weeks per cycle) were consistent in reducing HMB. In the proposed algorithm of treatment in the review, luteal phase progestogen was not encouraged and long‐cycle progestogen was only suggested as treatment for women with HMB not seeking pregnancy, those who did not wish to, or could not use an IUS, or those who preferred oral hormonal treatment (<a href="./references#CD001016-bbs2-0022" title="BitzerJ , HeikinheimoO , NelsonA , Calaf‐AlsinaJ , FraserI . Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstetrics and Gynecolgy Survey2015;70(2):115‐30. [10.1097/ogx.0000000000000155] ">Bitzer 2015</a>). </p> <p>The 2018 NICE guidelines for treating HMB (<a href="./references#CD001016-bbs2-0045" title="National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding: assessment and management. National Collaborating Centre for Women’s and Children’s Health Commissioned by the National Institute for Health and Clinical Excellence. www.nice.org.uk/guidance/ng882018. ">NICE 2018</a>), suggested that the LNG‐IUS should be the first‐line treatment for HMB in women without pathology, with fibroids less than 3 cm in diameter (and not causing distortion of the uterine cavity), or with suspected or diagnosed adenomyosis. The guideline reported that the available evidence did not show clinically important differences in effectiveness and acceptability among the other pharmacological treatments, so if a woman declines LNG‐IUS, or it is not suitable, there are several options that may be considered. Cyclical progestogens are included in these options, but the guideline did not specify which type, dosage or length of treatment. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001016-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram" data-id="CD001016-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials" data-id="CD001016-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial" data-id="CD001016-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 12: Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, outcome: 12.1 Bleeding PBAC after 3 months." data-id="CD001016-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 12: Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, outcome: 12.1 Bleeding PBAC after 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 1 Menstrual blood loss (alkaline haematin method)." data-id="CD001016-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 2 Duration of menstruation (days)." data-id="CD001016-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 2 Duration of menstruation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 3 Compliance with treatment." data-id="CD001016-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 3 Compliance with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 4 Adverse events (total)." data-id="CD001016-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 4 Adverse events (total). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 5 Adverse events ‐ headache." data-id="CD001016-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 5 Adverse events ‐ headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 6 Adverse events ‐ gastrointestinal symptoms." data-id="CD001016-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 6 Adverse events ‐ gastrointestinal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 7 Adverse events ‐ dysmenorrhoea." data-id="CD001016-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Progestogen therapy (luteal phase only) versus NSAIDs, Outcome 7 Adverse events ‐ dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 1 Menstrual blood loss (alkaline haematin method)." data-id="CD001016-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 2 Proportion of women with improvement in MBL (subjective)." data-id="CD001016-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 2 Proportion of women with improvement in MBL (subjective). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 3 Duration of menstruation (days)." data-id="CD001016-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 3 Duration of menstruation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 4 Compliance with treatment." data-id="CD001016-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 4 Compliance with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 5 Adverse events (total)." data-id="CD001016-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 5 Adverse events (total). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 6 Adverse events ‐ headache." data-id="CD001016-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 6 Adverse events ‐ headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 7 Adverse events ‐ gastrointestinal symptoms." data-id="CD001016-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 7 Adverse events ‐ gastrointestinal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 8 Adverse events ‐ weight gain." data-id="CD001016-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 8 Adverse events ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 9 Adverse events ‐ skin changes." data-id="CD001016-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 9 Adverse events ‐ skin changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 10 Adverse events ‐ neurological changes." data-id="CD001016-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 10 Adverse events ‐ neurological changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 11 Adverse events ‐ bloating." data-id="CD001016-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 11 Adverse events ‐ bloating. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 12 Adverse events ‐ voice changes." data-id="CD001016-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 12 Adverse events ‐ voice changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 13 Adverse events ‐ muscle cramps." data-id="CD001016-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 13 Adverse events ‐ muscle cramps. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 14 Adverse events ‐ intermenstrual bleeding." data-id="CD001016-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 14 Adverse events ‐ intermenstrual bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 15 Adverse events ‐ breast changes." data-id="CD001016-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Progestogen therapy (luteal phase only) versus danazol, Outcome 15 Adverse events ‐ breast changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 1 Menstrual blood loss (alkaline haematin method)." data-id="CD001016-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 2 Bleeding PBAC at 3 months." data-id="CD001016-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 2 Bleeding PBAC at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 3 Bleeding: improvement rates." data-id="CD001016-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 3 Bleeding: improvement rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 4 Satisfaction with treatment." data-id="CD001016-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 4 Satisfaction with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 5 Proportion with improvement in quality of life/dysmenorrhoea." data-id="CD001016-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 5 Proportion with improvement in quality of life/dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 6 Quality of life SF36." data-id="CD001016-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 6 Quality of life SF36. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 7 Adverse events (total)." data-id="CD001016-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 7 Adverse events (total). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 8 Adverse events ‐ headache." data-id="CD001016-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 8 Adverse events ‐ headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 9 Adverse events ‐ gastrointestinal symptoms." data-id="CD001016-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 9 Adverse events ‐ gastrointestinal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 10 Adverse events ‐ weight gain." data-id="CD001016-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 10 Adverse events ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 11 Adverse events ‐ bloating." data-id="CD001016-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 11 Adverse events ‐ bloating. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 12 Adverse events ‐ dysmenorrhoea." data-id="CD001016-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Progestogen therapy (luteal phase only) versus tranexamic acid, Outcome 12 Adverse events ‐ dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 1 Menstrual blood loss (alkaline haematin method)." data-id="CD001016-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 2 Improvement in MBL PBAC &lt; 100 at 6 months." data-id="CD001016-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 2 Improvement in MBL PBAC &lt; 100 at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 3 Satisfaction with treatment." data-id="CD001016-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 3 Satisfaction with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 4 Duration of menstruation (days)." data-id="CD001016-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 4 Duration of menstruation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 5 Quality of life." data-id="CD001016-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS, Outcome 5 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen therapy (MPA luteal phase only) versus LNG‐IUS, Outcome 1 Menstrual blood loss: PBAC reduction from baseline." data-id="CD001016-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Progestogen therapy (MPA luteal phase only) versus LNG‐IUS, Outcome 1 Menstrual blood loss: PBAC reduction from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progestogen therapy (MPA luteal phase only) versus LNG‐IUS, Outcome 2 Adverse effects." data-id="CD001016-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Progestogen therapy (MPA luteal phase only) versus LNG‐IUS, Outcome 2 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0046"> <p> <div class="table" id="CD001016-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irvine 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median menstrual blood loss (range) after 3 months of NET: 20 mls (4‐137)<br/> Median menstrual blood loss (range) after 3 months of LNG IUS: 6 mls (0‐284)<br/> p=0.033, t=315.5, Wilcoxon rank‐sum test, n=44 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0046">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001016-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 2 Proportion of women with MBL &lt; 80 mL after treatment." data-id="CD001016-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 2 Proportion of women with MBL &lt; 80 mL after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 3 PBAC at 3 months." data-id="CD001016-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 3 PBAC at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 4 PBAC at 6 months." data-id="CD001016-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 4 PBAC at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 5 Proportion with improvement in quality of life‐dysmenorrhoea." data-id="CD001016-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 5 Proportion with improvement in quality of life‐dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 6 Proportion who find treatment acceptable." data-id="CD001016-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 6 Proportion who find treatment acceptable. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 7 Adverse events ‐ intermenstrual bleeding." data-id="CD001016-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 7 Adverse events ‐ intermenstrual bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 8 Adverse events ‐ breast tenderness." data-id="CD001016-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 8 Adverse events ‐ breast tenderness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 9 Adverse events ‐ mood swings." data-id="CD001016-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Progestogen therapy (3 to 4 weeks) versus LNG‐IUS, Outcome 9 Adverse events ‐ mood swings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 1 Bleeding PBAC at 3 months." data-id="CD001016-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 1 Bleeding PBAC at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 2 Bleeding: improvement rate." data-id="CD001016-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 2 Bleeding: improvement rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 3 Quality of life SF‐36." data-id="CD001016-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 3 Quality of life SF‐36. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 4 Adverse effects." data-id="CD001016-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Progestogen therapy (3 to 4 weeks) versus tranexamic, Outcome 4 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 1 Menstrual blood loss: PBAC after 3 cycles." data-id="CD001016-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 1 Menstrual blood loss: PBAC after 3 cycles. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0060"> <p> <div class="table" id="CD001016-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conclusion/comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hashim 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Pg (NET) versus CVR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N = 95 (47 in NET group and 48 in CVR group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) PBAC score reduction (no measure of variation reported)</p> <p>NET: 69.5</p> <p>CVR: 68.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors concluded that there were no differences between randomised groups</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 2 Percentage reduction in MBL (at end of study). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0060">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001016-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 3 Satisfaction with treatment." data-id="CD001016-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 3 Satisfaction with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 4 Quality of life (HRQoL‐4 self‐rated health)." data-id="CD001016-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 4 Quality of life (HRQoL‐4 self‐rated health). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 5 Quality of life (HRQoL‐4 impairment or lost days)." data-id="CD001016-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 5 Quality of life (HRQoL‐4 impairment or lost days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 6 Adverse events." data-id="CD001016-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Progestogen therapy (3‐4 weeks) versus combined vaginal ring, Outcome 6 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 1 Menstrual blood loss (alkaline haematin method)." data-id="CD001016-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 1 Menstrual blood loss (alkaline haematin method). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 2 Satisfaction." data-id="CD001016-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 2 Satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 3 Menstruation days." data-id="CD001016-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 3 Menstruation days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 4 Quality of life: physical functioning." data-id="CD001016-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 4 Quality of life: physical functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 5 Total adverse effects." data-id="CD001016-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy, Outcome 5 Total adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 1 Bleeding PBAC after 3 months." data-id="CD001016-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 1 Bleeding PBAC after 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 2 Bleeding PBAC after 6 months." data-id="CD001016-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 2 Bleeding PBAC after 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 3 Satisfaction." data-id="CD001016-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 3 Satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 4 Treatment acceptability." data-id="CD001016-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 4 Treatment acceptability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 5 Adverse effect ‐ headache." data-id="CD001016-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 5 Adverse effect ‐ headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001016-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/urn:x-wiley:14651858:media:CD001016:CD001016-CMP-012-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_t/tCD001016-CMP-012-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 6 Adverse effect ‐ breakthrough bleeding/spotting." data-id="CD001016-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy, Outcome 6 Adverse effect ‐ breakthrough bleeding/spotting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/media/CDSR/CD001016/image_n/nCD001016-CMP-012-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001016-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> progestogen therapy, luteal phase only<br/> <b>Comparison:</b> other medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other medical treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen therapy (luteal phase only)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> Assessed with alkaline haematin method </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean menstrual blood loss ranged from 51 to 97</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 37.29 higher<br/> (17.67 higher to 56.91 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>738 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>693 per 1000<br/> (324 to 915) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.80<br/> (0.17 to 3.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days of bleeding</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of bleeding ranged from 2 to 7 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.05 days more<br/> (0.69 more to 1.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Physical functioning </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: physical functioning was 14.12</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.43 lower</p> <p>5.10 lower to 4.24 higher</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>680 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000<br/> (433 to 731) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.68<br/> (0.36 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> </p> <p>further research is very unlikely to change our confidence in the estimate of effect.</p> <p><b>Moderate quality:</b> </p> <p>further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> </p> <p>further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> </p> <p>we are very uncertain about the estimate.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to moderate heterogeneity.<br/> <sup>b</sup>There are two different luteal phase progestogens, so we downgraded the evidence for this outcome by 1 level.<br/> <sup>c</sup>Downgraded two levels for high risk of detection and attrition bias.<br/> <sup>d</sup>Based only on one trial, downgraded one level.<br/> <sup>e</sup>Downgraded two levels due to high heterogeneity (&gt; 75%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Progestogen therapy (luteal phase only) compared to other medical therapy for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001016-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with heavy menstrual bleeding<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> progestogen therapy long cycle (3 to 4 weeks)<br/> <b>Comparison:</b> other medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with progestogen long cycle (3 to 4 weeks)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> PBAC after 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding PBAC after 3 months ranged from 92‐155</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 16.88 more<br/> (10.93 more to 22.84 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Menstrual blood loss</b><br/> PBAC after 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding PBAC after 6 months was 80</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 21.42 more<br/> (14.24 more to 28.6 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>708 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>430 per 1000</p> <p>(240 to 633)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.31</p> <p>(0.13 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Days of bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported in any trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of lif</b>e </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported in any trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> <p>Headache</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (18 to 194) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.45<br/> (0.40 to 5.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect</b> </p> <p>Breakthrough bleeding/spotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (14 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.18<br/> (0.06 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; MD: mean difference; <b>OR:</b> Odds ratio; <b>PBAC:</b> Pictorial Blood Assessment Chart; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> </p> <p>further research is very unlikely to change our confidence in the estimate of effect.</p> <p><b>Moderate quality:</b> </p> <p>further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> </p> <p>further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> </p> <p>we are very uncertain about the estimate.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of detection bias. Unknown risk of selection bias. Downgraded one level.<br/> <sup>b</sup>Based only on one trial, downgraded one level.<br/> <sup>c</sup>All the trials had a high risk of detection bias and unknown risk of selection bias. One had high risk of attrition bias. Downgraded two levels. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progestogen therapy long cycle (3 to 4 weeks) compared to other medical therapy for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/full#CD001016-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogen therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1 Menstrual blood loss (alkaline haematin method)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2 Proportion of women with no improvement in MBL (subjective)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3 Duration of menstruation (days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4 Proportion with no improvement in quality of life ‐ dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5 Proportion of participant non‐compliance with treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6 Proportion of women who find treatment unacceptable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7 Adverse events (total)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Adverse events ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Adverse events ‐ gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Adverse events ‐ weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11 Adverse events ‐ skin changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12 Adverse events ‐ neurological symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13 Adverse events ‐ bloating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14 Adverse events ‐ voice changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15 Adverse events ‐ dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progestogen therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.97 [‐0.62, 46.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Duration of menstruation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.13, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Compliance with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.05, 14.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.44, 7.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.35, 7.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events ‐ gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 5.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events ‐ dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.20, 6.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus danazol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>55.63 [14.73, 96.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of women with improvement in MBL (subjective) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.08, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of menstruation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.10, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Compliance with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.45, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.09, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events ‐ gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.06, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.09, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events ‐ skin changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events ‐ neurological changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.20, 4.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events ‐ bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.04, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events ‐ voice changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [0.34, 106.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events ‐ muscle cramps <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.28, 7.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events ‐ intermenstrual bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.04, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events ‐ breast changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.73 [1.14, 67.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus danazol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus tranexamic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>111.0 [43.54, 178.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding PBAC at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.0 [‐15.54, 65.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Bleeding: improvement rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.25, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Satisfaction with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.37, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion with improvement in quality of life/dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Improvement in general health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.14, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Improvement in dysmenorrhoea symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Improvement in ability to enjoy social activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.13, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Improvement in flooding or leakage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Improvement in sex life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life SF36 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.48, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐2.25, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐2.46, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.73, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Environmental domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.57, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.33, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.59, 6.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events ‐ gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.54, 5.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events ‐ bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.61 [0.52, 142.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events ‐ dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.32, 6.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progestogen therapy (luteal phase only) versus tranexamic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>51.0 [18.38, 83.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Improvement in MBL PBAC &lt; 100 at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Satisfaction with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.10, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of menstruation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.19, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐3.18, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Physical domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐6.21, 6.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Psychological domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐7.49, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Social domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐9.33, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Environmental domain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐6.34, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Environmental domain‐TR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐6.14, 5.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progestogen therapy (NE luteal phase only) versus Progestogen‐ IUS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progestogen therapy (MPA luteal phase only) versus LNG‐IUS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: PBAC reduction from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.3 [‐69.91, ‐28.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.82, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ovarian cyst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.07, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pelvic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.10, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.64, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.16, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Vaginitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.93, 9.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.29, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Hypertention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [0.80, 20.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.42, 7.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.40, 10.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.54, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Increased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.21, 3.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progestogen therapy (MPA luteal phase only) versus LNG‐IUS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progestogen therapy (3 to 4 weeks) versus LNG‐IUS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of women with MBL &lt; 80 mL after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.09, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PBAC at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.00 [‐609.14, 667.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PBAC at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.42 [14.24, 28.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion with improvement in quality of life‐dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.42, 10.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proportion who find treatment acceptable <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events ‐ intermenstrual bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events ‐ breast tenderness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events ‐ mood swings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.19, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progestogen therapy (3 to 4 weeks) versus LNG‐IUS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Progestogen therapy (3 to 4 weeks) versus tranexamic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding PBAC at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.82 [‐12.09, 29.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding: improvement rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.07, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life SF‐36 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐3.33, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐6.77, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Role physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐13.63, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐6.01, 11.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐12.49, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐9.42, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐5.36, 7.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Role emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐11.47, 12.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐4.83, 10.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.16, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Gastrointestinal events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.23, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.23, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.81 [0.13, 344.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Intermenstrual bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.02, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Giddiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Mood changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.00, 6.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Progestogen therapy (3 to 4 weeks) versus tranexamic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Progestogen therapy (3‐4 weeks) versus combined vaginal ring</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss: PBAC after 3 cycles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐8.15, 12.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percentage reduction in MBL (at end of study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Satisfaction with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life (HRQoL‐4 self‐rated health) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.33, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life (HRQoL‐4 impairment or lost days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Number of days feeling physically unwell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.28, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Number of days feeling mentally unwell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.10, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Number of lost days (with no regular activity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.38, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.20, 19.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.26, 9.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Breakthrough bleeding/spotting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [0.71, 12.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Leukorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.05, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Vaginal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Vaginitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 1.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Progestogen therapy (3‐4 weeks) versus combined vaginal ring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual blood loss (alkaline haematin method) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>37.29 [17.67, 56.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Versus NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.78 [‐9.00, 42.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Versus danazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>56.25 [12.03, 100.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>111.0 [43.54, 178.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Versus Pg‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>51.0 [‐1.51, 103.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.17, 3.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.12, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Versus LNG‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.06, 8.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menstruation days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Versus NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.13, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Versus danazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.10, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Versus Pg‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.19, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life: physical functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐5.10, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐6.71, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 versus LNG‐ IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐7.45, 7.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Versus NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.43, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Versus danazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.12, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.32, 2.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Overall analysis 1: progestogen therapy (luteal phase only) versus other medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001016-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding PBAC after 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.88 [10.93, 22.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Versus LNG‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.0 [21.20, 36.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.82 [‐12.09, 29.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Versus combined vaginal ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐12.35, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding PBAC after 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.42 [14.24, 28.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Versus LNG‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.42 [14.24, 28.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment acceptability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Compared to LNG‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effect ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.40, 5.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.22, 8.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Versus combined vaginal ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.24, 9.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effect ‐ breakthrough bleeding/spotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Versus LNG‐IUS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.03, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Versus tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Versus combined vaginal ring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Overall analysis 2: progestogen therapy long cycle (3‐4 weeks) versus other medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001016.pub3/references#CD001016-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001016.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001016-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001016-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001016-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD001016-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001016-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD001016-note-0001">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001016-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001016\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001016\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001016\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001016\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001016\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001016.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001016.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001016.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001016.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001016.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717776094"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001016.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717776098"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001016.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc02e8fed936b',t:'MTc0MDcxNzc3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 